{"answers": [{"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [109], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [99], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [95], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [50], "text": ["vascular endothelial growth factor receptors"]}, {"answer_start": [0], "text": ["systemic lupus erythematosus"]}, {"answer_start": [0], "text": ["systemic lupus erythematosus"]}, {"answer_start": [0], "text": ["systemic lupus erythematosus"]}, {"answer_start": [0], "text": ["systemic lupus erythematosus"]}, {"answer_start": [0], "text": ["systemic lupus erythematosus"]}, {"answer_start": [0], "text": ["systemic lupus erythematosus"]}, {"answer_start": [0], "text": ["systemic lupus erythematosus"]}, {"answer_start": [0], "text": ["systemic lupus erythematosus"]}, {"answer_start": [154], "text": ["systemic lupus erythematosus"]}, {"answer_start": [154], "text": ["systemic lupus erythematosus"]}, {"answer_start": [154], "text": ["systemic lupus erythematosus"]}, {"answer_start": [154], "text": ["systemic lupus erythematosus"]}, {"answer_start": [154], "text": ["systemic lupus erythematosus"]}, {"answer_start": [154], "text": ["systemic lupus erythematosus"]}, {"answer_start": [154], "text": ["systemic lupus erythematosus"]}, {"answer_start": [154], "text": ["systemic lupus erythematosus"]}, {"answer_start": [134], "text": ["systemic lupus erythematosus"]}, {"answer_start": [134], "text": ["systemic lupus erythematosus"]}, {"answer_start": [134], "text": ["systemic lupus erythematosus"]}, {"answer_start": [134], "text": ["systemic lupus erythematosus"]}, {"answer_start": [134], "text": ["systemic lupus erythematosus"]}, {"answer_start": [134], "text": ["systemic lupus erythematosus"]}, {"answer_start": [134], "text": ["systemic lupus erythematosus"]}, {"answer_start": [134], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [209], "text": ["systemic lupus erythematosus"]}, {"answer_start": [208], "text": ["systemic lupus erythematosus"]}, {"answer_start": [208], "text": ["systemic lupus erythematosus"]}, {"answer_start": [208], "text": ["systemic lupus erythematosus"]}, {"answer_start": [208], "text": ["systemic lupus erythematosus"]}, {"answer_start": [208], "text": ["systemic lupus erythematosus"]}, {"answer_start": [208], "text": ["systemic lupus erythematosus"]}, {"answer_start": [208], "text": ["systemic lupus erythematosus"]}, {"answer_start": [208], "text": ["systemic lupus erythematosus"]}, {"answer_start": [135], "text": ["systemic lupus erythematosus"]}, {"answer_start": [135], "text": ["systemic lupus erythematosus"]}, {"answer_start": [135], "text": ["systemic lupus erythematosus"]}, {"answer_start": [135], "text": ["systemic lupus erythematosus"]}, {"answer_start": [135], "text": ["systemic lupus erythematosus"]}, {"answer_start": [135], "text": ["systemic lupus erythematosus"]}, {"answer_start": [135], "text": ["systemic lupus erythematosus"]}, {"answer_start": [135], "text": ["systemic lupus erythematosus"]}, {"answer_start": [113], "text": ["systemic lupus erythematosus"]}, {"answer_start": [113], "text": ["systemic lupus erythematosus"]}, {"answer_start": [113], "text": ["systemic lupus erythematosus"]}, {"answer_start": [113], "text": ["systemic lupus erythematosus"]}, {"answer_start": [113], "text": ["systemic lupus erythematosus"]}, {"answer_start": [113], "text": ["systemic lupus erythematosus"]}, {"answer_start": [113], "text": ["systemic lupus erythematosus"]}, {"answer_start": [113], "text": ["systemic lupus erythematosus"]}, {"answer_start": [86], "text": ["systemic lupus erythematosus"]}, {"answer_start": [86], "text": ["systemic lupus erythematosus"]}, {"answer_start": [86], "text": ["systemic lupus erythematosus"]}, {"answer_start": [86], "text": ["systemic lupus erythematosus"]}, {"answer_start": [86], "text": ["systemic lupus erythematosus"]}, {"answer_start": [86], "text": ["systemic lupus erythematosus"]}, {"answer_start": [86], "text": ["systemic lupus erythematosus"]}, {"answer_start": [86], "text": ["systemic lupus erythematosus"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [75], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [94], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [52], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [55], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [60], "text": ["cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [33, 117], "text": ["cytoplasm", "cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [43], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [68], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [26], "text": ["cytoplasm"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [38], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [23], "text": ["vestibular schwannomas"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [39], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [140], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [117], "text": ["omodysplasia"]}, {"answer_start": [64], "text": ["70"]}, {"answer_start": [64], "text": ["70"]}, {"answer_start": [64], "text": ["70"]}, {"answer_start": [64], "text": ["70"]}, {"answer_start": [64], "text": ["70"]}, {"answer_start": [64], "text": ["70"]}, {"answer_start": [64], "text": ["70"]}, {"answer_start": [64], "text": ["70"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [641], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [32], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [31], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [19], "text": ["55"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [294], "text": ["short arm of chromosome 19"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [0], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [19], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [11], "text": ["helicobacter pylori"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [84], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [32], "text": ["oxidative burst"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [199], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [64], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [66], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [35], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [37], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [43], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [42], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [52], "text": ["dominant"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [206], "text": ["heterochromatic gene silencing"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [92, 207], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [90], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [84, 166], "text": ["calcitonin gene-related peptide", "calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [111], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [106], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [68], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [125], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [132], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [54], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [64], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [49], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [69], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [53], "text": ["calcitonin gene-related peptide"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [104], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [103], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [98], "text": ["carotid and vertebral artery dissection"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [11], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [60], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [101], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [26], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [24], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [22], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [136], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [75], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [39], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [23], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [30], "text": ["sphingosine-1-phosphate"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [234], "text": ["80-100%"]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [54], "text": ["attachment and fusion during viral entry as well as for the induction of cell to cell fusion."]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [180], "text": ["1983"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [137], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [136], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [193], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [69], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [81], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [118], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [50], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [108], "text": ["camel"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [900], "text": ["5,000"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [25, 255], "text": ["multiple sclerosis", "multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [111], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [110], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [133], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [97], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [96], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [33], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [48], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [73], "text": ["multiple sclerosis"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [615, 726, 1089, 1456], "text": ["melanocytes", "melanocytes", "melanocytes", "melanocytes"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [43], "text": ["polymerase"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [258], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [42], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [146], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [143], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [124], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [111], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [44], "text": ["pituitary"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [66, 247], "text": ["antibiotics", "antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [9], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [50], "text": ["antibiotics"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [161, 260], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [39, 283, 332], "text": ["ulcerative colitis", "ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [155], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [238], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [231], "text": ["ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [17, 157], "text": ["ulcerative colitis", "ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [91], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [0], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [89], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [82], "text": ["ulcerative colitis"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [44], "text": ["programmed death-1"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [8], "text": ["3' flanking region"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [100], "text": ["apoptosis"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [28], "text": [">200 nucleotides"]}, {"answer_start": [20], "text": ["prominent small vessels"]}, {"answer_start": [20], "text": ["prominent small vessels"]}, {"answer_start": [65], "text": ["transdermal drug-coated microneedle patch system"]}, {"answer_start": [65], "text": ["transdermal drug-coated microneedle patch system"]}, {"answer_start": [65], "text": ["transdermal drug-coated microneedle patch system"]}, {"answer_start": [65], "text": ["transdermal drug-coated microneedle patch system"]}, {"answer_start": [65], "text": ["transdermal drug-coated microneedle patch system"]}, {"answer_start": [65], "text": ["transdermal drug-coated microneedle patch system"]}, {"answer_start": [65], "text": ["transdermal drug-coated microneedle patch system"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [18], "text": ["senktide"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [134], "text": ["immune cells"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [47], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}, {"answer_start": [78], "text": ["20"]}], "context": ["background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "background: tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "background: tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.", "systemic lupus erythematosus (sle) is an autoimmune disease with a polymorphic presentation. the variability in the clinical expression and severity of sle makes new treatments both essential and challenging to develop. several biotherapies targeting different pathophysiological pathways have been developed over the past 15 years. the results of phase ii trials were encouraging but rarely borne out by phase iii trials. recent data, which are discussed in detail in this review, allowed belimumab\u00a0-\u00a0a monoclonal antibody against blys (b-lymphocyte stimulator)\u00a0-\u00a0to become the first biotherapy approved for use in sle. other molecules targeting b cells include the two anti-blys antibodies tabalumab and blisibimod; atacicept, which targets both blys and april (a proliferation-inducing ligand); and the monoclonal antibody to cd22 epratuzumab. the rekindling of interest in the b-cell pathway has also driven new clinical research into rituximab, a monoclonal antibody targeting cd20 with evaluations of new strategies. a new and promising approach is the use of inhibitors of the type 1 interferon (ifn) pathway, of which the most promising is anifrolumab, a monoclonal antibody targeting the type 1 ifn receptor.", "systemic lupus erythematosus (sle) is an autoimmune disease with a polymorphic presentation. the variability in the clinical expression and severity of sle makes new treatments both essential and challenging to develop. several biotherapies targeting different pathophysiological pathways have been developed over the past 15 years. the results of phase ii trials were encouraging but rarely borne out by phase iii trials. recent data, which are discussed in detail in this review, allowed belimumab\u00a0-\u00a0a monoclonal antibody against blys (b-lymphocyte stimulator)\u00a0-\u00a0to become the first biotherapy approved for use in sle. other molecules targeting b cells include the two anti-blys antibodies tabalumab and blisibimod; atacicept, which targets both blys and april (a proliferation-inducing ligand); and the monoclonal antibody to cd22 epratuzumab. the rekindling of interest in the b-cell pathway has also driven new clinical research into rituximab, a monoclonal antibody targeting cd20 with evaluations of new strategies. a new and promising approach is the use of inhibitors of the type 1 interferon (ifn) pathway, of which the most promising is anifrolumab, a monoclonal antibody targeting the type 1 ifn receptor.", "systemic lupus erythematosus (sle) is an autoimmune disease with a polymorphic presentation. the variability in the clinical expression and severity of sle makes new treatments both essential and challenging to develop. several biotherapies targeting different pathophysiological pathways have been developed over the past 15 years. the results of phase ii trials were encouraging but rarely borne out by phase iii trials. recent data, which are discussed in detail in this review, allowed belimumab\u00a0-\u00a0a monoclonal antibody against blys (b-lymphocyte stimulator)\u00a0-\u00a0to become the first biotherapy approved for use in sle. other molecules targeting b cells include the two anti-blys antibodies tabalumab and blisibimod; atacicept, which targets both blys and april (a proliferation-inducing ligand); and the monoclonal antibody to cd22 epratuzumab. the rekindling of interest in the b-cell pathway has also driven new clinical research into rituximab, a monoclonal antibody targeting cd20 with evaluations of new strategies. a new and promising approach is the use of inhibitors of the type 1 interferon (ifn) pathway, of which the most promising is anifrolumab, a monoclonal antibody targeting the type 1 ifn receptor.", "systemic lupus erythematosus (sle) is an autoimmune disease with a polymorphic presentation. the variability in the clinical expression and severity of sle makes new treatments both essential and challenging to develop. several biotherapies targeting different pathophysiological pathways have been developed over the past 15 years. the results of phase ii trials were encouraging but rarely borne out by phase iii trials. recent data, which are discussed in detail in this review, allowed belimumab\u00a0-\u00a0a monoclonal antibody against blys (b-lymphocyte stimulator)\u00a0-\u00a0to become the first biotherapy approved for use in sle. other molecules targeting b cells include the two anti-blys antibodies tabalumab and blisibimod; atacicept, which targets both blys and april (a proliferation-inducing ligand); and the monoclonal antibody to cd22 epratuzumab. the rekindling of interest in the b-cell pathway has also driven new clinical research into rituximab, a monoclonal antibody targeting cd20 with evaluations of new strategies. a new and promising approach is the use of inhibitors of the type 1 interferon (ifn) pathway, of which the most promising is anifrolumab, a monoclonal antibody targeting the type 1 ifn receptor.", "systemic lupus erythematosus (sle) is an autoimmune disease with a polymorphic presentation. the variability in the clinical expression and severity of sle makes new treatments both essential and challenging to develop. several biotherapies targeting different pathophysiological pathways have been developed over the past 15 years. the results of phase ii trials were encouraging but rarely borne out by phase iii trials. recent data, which are discussed in detail in this review, allowed belimumab\u00a0-\u00a0a monoclonal antibody against blys (b-lymphocyte stimulator)\u00a0-\u00a0to become the first biotherapy approved for use in sle. other molecules targeting b cells include the two anti-blys antibodies tabalumab and blisibimod; atacicept, which targets both blys and april (a proliferation-inducing ligand); and the monoclonal antibody to cd22 epratuzumab. the rekindling of interest in the b-cell pathway has also driven new clinical research into rituximab, a monoclonal antibody targeting cd20 with evaluations of new strategies. a new and promising approach is the use of inhibitors of the type 1 interferon (ifn) pathway, of which the most promising is anifrolumab, a monoclonal antibody targeting the type 1 ifn receptor.", "systemic lupus erythematosus (sle) is an autoimmune disease with a polymorphic presentation. the variability in the clinical expression and severity of sle makes new treatments both essential and challenging to develop. several biotherapies targeting different pathophysiological pathways have been developed over the past 15 years. the results of phase ii trials were encouraging but rarely borne out by phase iii trials. recent data, which are discussed in detail in this review, allowed belimumab\u00a0-\u00a0a monoclonal antibody against blys (b-lymphocyte stimulator)\u00a0-\u00a0to become the first biotherapy approved for use in sle. other molecules targeting b cells include the two anti-blys antibodies tabalumab and blisibimod; atacicept, which targets both blys and april (a proliferation-inducing ligand); and the monoclonal antibody to cd22 epratuzumab. the rekindling of interest in the b-cell pathway has also driven new clinical research into rituximab, a monoclonal antibody targeting cd20 with evaluations of new strategies. a new and promising approach is the use of inhibitors of the type 1 interferon (ifn) pathway, of which the most promising is anifrolumab, a monoclonal antibody targeting the type 1 ifn receptor.", "systemic lupus erythematosus (sle) is an autoimmune disease with a polymorphic presentation. the variability in the clinical expression and severity of sle makes new treatments both essential and challenging to develop. several biotherapies targeting different pathophysiological pathways have been developed over the past 15 years. the results of phase ii trials were encouraging but rarely borne out by phase iii trials. recent data, which are discussed in detail in this review, allowed belimumab\u00a0-\u00a0a monoclonal antibody against blys (b-lymphocyte stimulator)\u00a0-\u00a0to become the first biotherapy approved for use in sle. other molecules targeting b cells include the two anti-blys antibodies tabalumab and blisibimod; atacicept, which targets both blys and april (a proliferation-inducing ligand); and the monoclonal antibody to cd22 epratuzumab. the rekindling of interest in the b-cell pathway has also driven new clinical research into rituximab, a monoclonal antibody targeting cd20 with evaluations of new strategies. a new and promising approach is the use of inhibitors of the type 1 interferon (ifn) pathway, of which the most promising is anifrolumab, a monoclonal antibody targeting the type 1 ifn receptor.", "systemic lupus erythematosus (sle) is an autoimmune disease with a polymorphic presentation. the variability in the clinical expression and severity of sle makes new treatments both essential and challenging to develop. several biotherapies targeting different pathophysiological pathways have been developed over the past 15 years. the results of phase ii trials were encouraging but rarely borne out by phase iii trials. recent data, which are discussed in detail in this review, allowed belimumab\u00a0-\u00a0a monoclonal antibody against blys (b-lymphocyte stimulator)\u00a0-\u00a0to become the first biotherapy approved for use in sle. other molecules targeting b cells include the two anti-blys antibodies tabalumab and blisibimod; atacicept, which targets both blys and april (a proliferation-inducing ligand); and the monoclonal antibody to cd22 epratuzumab. the rekindling of interest in the b-cell pathway has also driven new clinical research into rituximab, a monoclonal antibody targeting cd20 with evaluations of new strategies. a new and promising approach is the use of inhibitors of the type 1 interferon (ifn) pathway, of which the most promising is anifrolumab, a monoclonal antibody targeting the type 1 ifn receptor.", "a post-hoc analysis of pooled data from two phase iib trials (sifalimumab; nct01283139, anifrolumab; nct01438489) assessed the clinical significance of a systemic lupus erythematosus (sle) responder index (sri(4)) response (week 52) for 736 patients with moderate to severe sle disease activity (study entry).", "a post-hoc analysis of pooled data from two phase iib trials (sifalimumab; nct01283139, anifrolumab; nct01438489) assessed the clinical significance of a systemic lupus erythematosus (sle) responder index (sri(4)) response (week 52) for 736 patients with moderate to severe sle disease activity (study entry).", "a post-hoc analysis of pooled data from two phase iib trials (sifalimumab; nct01283139, anifrolumab; nct01438489) assessed the clinical significance of a systemic lupus erythematosus (sle) responder index (sri(4)) response (week 52) for 736 patients with moderate to severe sle disease activity (study entry).", "a post-hoc analysis of pooled data from two phase iib trials (sifalimumab; nct01283139, anifrolumab; nct01438489) assessed the clinical significance of a systemic lupus erythematosus (sle) responder index (sri(4)) response (week 52) for 736 patients with moderate to severe sle disease activity (study entry).", "a post-hoc analysis of pooled data from two phase iib trials (sifalimumab; nct01283139, anifrolumab; nct01438489) assessed the clinical significance of a systemic lupus erythematosus (sle) responder index (sri(4)) response (week 52) for 736 patients with moderate to severe sle disease activity (study entry).", "a post-hoc analysis of pooled data from two phase iib trials (sifalimumab; nct01283139, anifrolumab; nct01438489) assessed the clinical significance of a systemic lupus erythematosus (sle) responder index (sri(4)) response (week 52) for 736 patients with moderate to severe sle disease activity (study entry).", "a post-hoc analysis of pooled data from two phase iib trials (sifalimumab; nct01283139, anifrolumab; nct01438489) assessed the clinical significance of a systemic lupus erythematosus (sle) responder index (sri(4)) response (week 52) for 736 patients with moderate to severe sle disease activity (study entry).", "a post-hoc analysis of pooled data from two phase iib trials (sifalimumab; nct01283139, anifrolumab; nct01438489) assessed the clinical significance of a systemic lupus erythematosus (sle) responder index (sri(4)) response (week 52) for 736 patients with moderate to severe sle disease activity (study entry).", "objectives: in a post-hoc analysis, we aimed to validate the lupus low disease activity state (lldas) definition as an endpoint in an systemic lupus erythematosus (sle) phase iib randomised controlled trial (rct) (muse [nct01438489]) and then utilize lldas to discriminate between anifrolumab and placebo", "objectives: in a post-hoc analysis, we aimed to validate the lupus low disease activity state (lldas) definition as an endpoint in an systemic lupus erythematosus (sle) phase iib randomised controlled trial (rct) (muse [nct01438489]) and then utilize lldas to discriminate between anifrolumab and placebo", "objectives: in a post-hoc analysis, we aimed to validate the lupus low disease activity state (lldas) definition as an endpoint in an systemic lupus erythematosus (sle) phase iib randomised controlled trial (rct) (muse [nct01438489]) and then utilize lldas to discriminate between anifrolumab and placebo", "objectives: in a post-hoc analysis, we aimed to validate the lupus low disease activity state (lldas) definition as an endpoint in an systemic lupus erythematosus (sle) phase iib randomised controlled trial (rct) (muse [nct01438489]) and then utilize lldas to discriminate between anifrolumab and placebo", "objectives: in a post-hoc analysis, we aimed to validate the lupus low disease activity state (lldas) definition as an endpoint in an systemic lupus erythematosus (sle) phase iib randomised controlled trial (rct) (muse [nct01438489]) and then utilize lldas to discriminate between anifrolumab and placebo", "objectives: in a post-hoc analysis, we aimed to validate the lupus low disease activity state (lldas) definition as an endpoint in an systemic lupus erythematosus (sle) phase iib randomised controlled trial (rct) (muse [nct01438489]) and then utilize lldas to discriminate between anifrolumab and placebo", "objectives: in a post-hoc analysis, we aimed to validate the lupus low disease activity state (lldas) definition as an endpoint in an systemic lupus erythematosus (sle) phase iib randomised controlled trial (rct) (muse [nct01438489]) and then utilize lldas to discriminate between anifrolumab and placebo", "objectives: in a post-hoc analysis, we aimed to validate the lupus low disease activity state (lldas) definition as an endpoint in an systemic lupus erythematosus (sle) phase iib randomised controlled trial (rct) (muse [nct01438489]) and then utilize lldas to discriminate between anifrolumab and placebo", "objective\n\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\n\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\n\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\n\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\n\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\n\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\n\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\n\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective: to assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective: to assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective: to assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective: to assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective: to assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective: to assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective: to assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective: to assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "objective\nto assess the efficacy and safety of anifrolumab, a type i interferon (ifn) receptor antagonist, in a phase iib, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (sle).", "anifrolumab effects on rash and arthritis: impact of the type i interferon gene signature in the phase iib muse study in patients with systemic lupus erythematosus.", "anifrolumab effects on rash and arthritis: impact of the type i interferon gene signature in the phase iib muse study in patients with systemic lupus erythematosus.", "anifrolumab effects on rash and arthritis: impact of the type i interferon gene signature in the phase iib muse study in patients with systemic lupus erythematosus.", "anifrolumab effects on rash and arthritis: impact of the type i interferon gene signature in the phase iib muse study in patients with systemic lupus erythematosus.", "anifrolumab effects on rash and arthritis: impact of the type i interferon gene signature in the phase iib muse study in patients with systemic lupus erythematosus.", "anifrolumab effects on rash and arthritis: impact of the type i interferon gene signature in the phase iib muse study in patients with systemic lupus erythematosus.", "anifrolumab effects on rash and arthritis: impact of the type i interferon gene signature in the phase iib muse study in patients with systemic lupus erythematosus.", "anifrolumab effects on rash and arthritis: impact of the type i interferon gene signature in the phase iib muse study in patients with systemic lupus erythematosus.", "characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.", "characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.", "characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.", "characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.", "characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.", "characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.", "characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.", "characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.", "anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.", "anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.", "anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.", "anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.", "anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.", "anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.", "anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.", "anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "stress granules are non-membranous structures that transiently form in the cytoplasm during cellular stress, where they promote translational repression of non-essential rnas and modulate cell signaling by sequestering key signal transduction proteins.", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "in this study, we firstly have examined this punctate pattern of sam68 re-localization in the cytoplasm, and observed the obvious recruitments of sam68 to the ev71-induced stress granules (sgs)", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "here, we show that rbfox2 is a novel constituent of cytoplasmic stress granules, the translational silencing machinery assembled in response to cellular stress.", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", "we have previously shown that adar1(p150) localized to cytoplasmic stress granules in hela cells following either oxidative or interferon-induced stress", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", ". we also show that oxidative stress recruits mutant fus to cytoplasmic stress granules where it is able to bind and sequester wild-type fus.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "stress prompted the formation of cytoplasmic granules in all subjects and in sporadic als fus mislocalization to the cytoplasm.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "sequestration of highly expressed mrnas in cytoplasmic granules, p-bodies, and stress granules enhances cell viability.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "proteins that contain a functional z-dna-binding domain localize to cytoplasmic stress granules.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "stress granules (sgs) are cytoplasmic granules that are formed in cells when stress occurs.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\n\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background: the koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "background\nthe koos classification of vestibular schwannomas is designed to stratify tumors based on extrameatal extension and compression of the brainstem.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "koos classification of vestibular schwannomas: a reliability study.", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "we now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (gpc6).", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "the proband had normal molecular analysis of the glypican 6 gene (gpc6), which was recently reported as a candidate for autosomal recessive omodysplasia", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "mutations in the heparan-sulfate proteoglycan glypican 6 (gpc6) impair endochondral ossification and cause recessive omodysplasia.", "here, we examine the structural and functional diversity of the 70 human krab-znf genes involved in the most recent primate sd events including genes that arose in the hominid lineag", "here, we examine the structural and functional diversity of the 70 human krab-znf genes involved in the most recent primate sd events including genes that arose in the hominid lineag", "here, we examine the structural and functional diversity of the 70 human krab-znf genes involved in the most recent primate sd events including genes that arose in the hominid lineag", "here, we examine the structural and functional diversity of the 70 human krab-znf genes involved in the most recent primate sd events including genes that arose in the hominid lineag", "here, we examine the structural and functional diversity of the 70 human krab-znf genes involved in the most recent primate sd events including genes that arose in the hominid lineag", "here, we examine the structural and functional diversity of the 70 human krab-znf genes involved in the most recent primate sd events including genes that arose in the hominid lineag", "here, we examine the structural and functional diversity of the 70 human krab-znf genes involved in the most recent primate sd events including genes that arose in the hominid lineag", "here, we examine the structural and functional diversity of the 70 human krab-znf genes involved in the most recent primate sd events including genes that arose in the hominid lineag", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "these lncrnas have specific characteristics, such as broader expression domains, that set them apart from other lncrnas. fourteen lncrnas have sequence similarity with the loci of the contemporary homologs of the lost protein-coding genes. we propose that selection acting on enhancer sequences is mostly responsible for retention of these regions. as an example of an rna element from a protein-coding ancestor that was retained in the lncrna, we describe in detail a short translated orf in the jpx lncrna that was derived from an upstream orf in a protein-coding gene and retains some of its functionality.conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas. some lncrnas inherited regulatory elements influencing transcription and translation from their protein-coding ancestors and those elements can influence the expression breadth and functionality of these lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\n\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions: we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions we estimate that ~ 55 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "conclusions\nwe estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "we estimate that\u2009~\u200955 annotated conserved human lncrnas are derived from parts of ancestral protein-coding genes, and loss of coding potential is thus a non-negligible source of new lncrnas.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "familial hypercholesterolemia (fh) is an autosomal dominant inherited metabolic disorder resulting in advanced vascular atherosclerosis and premature death, primarily from coronary artery disease. the primary defect is a mutation in the gene encoding for the plasma ldl receptor located on the short arm of chromosome 19.", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori) is a gram-negative bacteria infecting numerous people all over the world. it has been established that h. pylori play an important role in pathogenesis of gastritis, peptic ulcer and gastric cancer", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori (h. pylori), a gram-negative microaerophilic bacterial pathogen that colonizes the stomachs of more than half of all humans, is linked to chronic gastritis, peptic ulcers and gastric cancer.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "helicobacter pylori has been linked to chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "background helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "the human pathogen helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer.", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "strains of helicobacter pylori that cause ulcer or gastric cancer", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "neutrophil activation mediated by anti-pr3 antibodies was assessed by measuring the oxidative burst with a dihydrorhodamine assay", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "detectable activation event and oxidative burst by the dihydrorhodamine assay, as a late, detectable activation event", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "huntington's disease (hd) is an autosomal dominant neurodegenerative disease characterized by gradual deterioration of motor and cognitive functions and development of psychiatric deficits. animal models provide powerful means to study the pathological", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "the d4s10 locus, defined by the probe g8 and linked to the gene for huntington's disease (hd), has permitted us to identify individuals with a high probability of being homozygous for this autosomal dominant neurodegenerative disorder.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is a late onset, incurable, autosomal dominantly-inherited, progressive neuropsychiatric disease, characterised by chorea, changes in personality, mood and behaviour, and dementia.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an autosomal-dominant, progressive neurodegenerative disease characterized by movement disorder, psychiatric symptoms and cognitive decline.", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington's disease (hd) is an inherited ndd caused by autosomal-dominant expanded cag trinucleotide repeat mutation in the gene coding for huntingtin (htt).", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington disease is an autosomal-dominant neurodegenerative disease of mid-life onset caused by expansion of a polymorphic trinucleotide (cag) repeat.", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease is an autosomal dominant neurodegenerative disease caused by a toxic gain of function mutation in the huntingtin gene (htt)", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease (hd) is a genetically dominant neurodegenerative condition caused by an unique mutation in the disease gene huntingtin.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene.", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington's disease is a fatal autosomal dominant neurodegenerative disease caused by an abnormal cag expansion in huntingtin's gene", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "huntington disease (hd) is a well-defined autosomal dominant neurodegenerative disease caused by cag repeat expansions in hd gene.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "here we show that piwi, an argonaute/piwi protein family member that binds to piwi-interacting rnas (pirnas), strongly and specifically interacts with heterochromatin protein 1a (hp1a), a central player in heterochromatic gene silencing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "a galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "background: galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (cgrp) and has demonstrated efficacy in reducing migraine headache days (mhd) in patients with episodic and chronic migraine.", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "background safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (nct02163993) are reported here.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance: galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "importance\n\ngalcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab-gnlm (emgality\u2122; eli lilly and company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (cgrp) ligand.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab is a humanized immunoglobulin g (igg) monoclonal antibody (mab) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (cgrp), is effective for migraine prevention with a favorable safety profile.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "galcanezumab (ly2951742), a monoclonal antibody against calcitonin gene-related peptide (cgrp), is one of a novel class of new medicines for migraine prevention.", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "background: galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.design/", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "introduction galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\n\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims: cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "aims\ncadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "cadiss is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "functional sphingosine-1-phosphate (s1p) antagonists like fingolimod and siponimod (baf312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (eamg), the standard model of mg.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "siponimod (baf312) is a synthetic molecule belonging to the sphingosine-1-phosphate (s1p) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of b and t cells in secondary lymphoid organs.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "a high incidence of hemangiosarcoma (hsa) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (s1p1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions.", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 ( siponimod ) is a sphingosine-1-phosphate ( s1p ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor fty720 ( fingolimod", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "baf312 (siponimod) is a sphingosine-1-phosphate (s1p) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor fty720 (fingolimod).", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod is an s1pr (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "we validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "results: among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month cdp by 21% versus placebo in spms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "baf312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in pms.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the oral live cholera vaccine cvd 103-hgr (orochol, mutachol), the first genetically modified organism (gmo) used as vaccine, was in its time (launched 1993, switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "the coronavirus peplomer protein s is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "vivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella (ty21a) and reproduces the natural infection. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown , but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host , from which human infections may sporadically occur through the zoonotic transmission", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "the exact origin of mers-cov remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "while bats may be the primary reservoir for both viruses, sars coronavirus (sars-cov) likely crossed into humans from civets in china, and mers coronavirus (mers-cov) has been transmitted from camels in the middle east.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "hese data demonstrate a genetic link for each of these clusters to a camel and support the hypothesis that human mers-cov diversity results from multiple zoonotic introductions.", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "middle east respiratory syndrome coronavirus (mers-cov) is a zoonotic virus from camels causing significant mortality and morbidity in humans in the arabian peninsula", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "here, we use existing mers-cov sequence data to explore its phylodynamics in two of its known major hosts, humans and camels.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "ong-term mers-cov evolution occurs exclusively in camels, whereas humans act as a transient, and ultimately terminal host.", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "human outbreaks in the arabian peninsula are driven by seasonally varying zoonotic transfer of viruses from camels", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "proteins perform essential cellular functions as part of protein complexes, often in conjunction with rna, dna, metabolites and other small molecules. the genome encodes thousands of proteins but not all of them are expressed in every cell type; and expressed proteins are not active at all times. such diversity of protein expression and function accounts for the level of biological intricacy seen in nature. defining protein-protein interactions in protein complexes, and establishing the when, what and where of potential interactions, is therefore crucial to understanding the cellular function of any protein-especially those that have not been well studied by traditional molecular genetic approaches. we generated a large-scale resource of affinity-tagged expression-ready clones and used co-affinity purification combined with tandem mass-spectrometry to identify protein partners of nearly 5,000 drosophila melanogaster proteins. the resulting protein complex \"map\" provided a blueprint of metazoan protein complex organization. here we describe how the map has provided valuable insights into protein function in addition to generating hundreds of testable hypotheses. we also discuss recent technological advancements that will be critical in addressing the next generation of questions arising from the map.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "the central vein sign in multiple sclerosis lesions is present irrespective of the t2* sequence at 3 t. background and purpose\nprevious t2*-weighted magnetic resonance imaging (mri) studies have used white matter lesion (wml) central veins to distinguish multiple sclerosis (ms) from its mimics.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "importance\n\nthe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (ms) and not ms, mainly based on findings from ultrahigh-field magnetic resonance imaging (mri) studies.", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "objective: to assess the value of the central vein sign (cvs) on a clinical 3t scanner to distinguish between multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background: detection of a \"central vein sign\" (cvs) on flair* magnetic resonance imaging (mri) is highly specific and sensitive for multiple sclerosis (ms).", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose\n\nthe central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "background and purpose the central vein sign is a promising mr imaging diagnostic biomarker for multiple sclerosis.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "haematopoietic stem and progenitor cells (hspcs) require a specific microenvironment, the haematopoietic niche, which regulates hspc behaviour1,2. the location of this niche varies across species, but the evolutionary pressures that drive hspcs to different microenvironments remain unknown. the niche is located in the bone marrow in adult mammals, whereas it is found in other locations in non-mammalian vertebrates, for example, in the kidney marrow in teleost fish. here we show that a melanocyte umbrella above the kidney marrow protects hspcs against ultraviolet light in zebrafish. because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect hspcs against ultraviolet-light-induced dna damage. indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of dna damage in hspcs, as indicated by staining of cyclobutane pyrimidine dimers and have reduced numbers of hspcs, as shown by cmyb (also known as myb) expression. the umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate. during the transition from an aquatic to a terrestrial environment, hspcs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow. our studies reveal that melanocytes above the haematopoietic niche protect hspcs from ultraviolet-light-induced dna damage in aquatic vertebrates and suggest that during the transition to terrestrial life, ultraviolet light was an evolutionary pressure affecting the location of the haematopoietic niche.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "in non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown.", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. most cases of cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as cushing's disease", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "hypercortisolism due to an acth-secreting pituitary adenoma (cushing's disease) is a chronic condition associated with high morbidity and mortality if inadequately managed.", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing 's disease ( cd ) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare endocrine disorder associated with increased serum levels of cortisol secreted due to an underlying tumour in pituitary.", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease (cd) is a rare disabling condition caused by adrenocorticotropic hormone (acth)-secreting adenomas of the pituitary", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (acth) from a pituitary adenoma.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "cushing's syndrome due to an acth-secreting pituitary tumor is associated with serious morbidity and mortality.", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. in the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant s. aureus both in vitro and in an experimental galleria mellonella model", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "results and conclusion: a high correlation was demonstrated between three of the 11 evaluated clinical indices - improvement based on individual symptom scores, ulcerative colitis disease activity index, and schroeder index - and all nine endoscopic indices - ulcerative colitis endoscopic index of severity, baron score, schroeder index, feagan index, powell-tuck index, rachmilewitz index, sutherland index, lofberg index, and lemman index.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "at present, many endoscopic indices of ulcerative colitis have been introduced, including the truelove and witts endoscopy index, baron index, powell-tuck index, sutherland index, mayo clinic endoscopic sub-score, rachmilewitz index, modified baron index, endoscopic activity index, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and modified mayo endoscopic score.", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "background: to investigate whether anxiety and depression levels are associated with heat shock protein 70 (hsp70) induction in the colon of patients with ulcerative colitis (uc).methods: the design was cross-sectional. clinical activity was assessed by the rachmilewitz index (cai).", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective: the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).subjects and", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "objective\n\nthe aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index (eai) and the harpaz histopathological activity scoring system (hss), which are used for evaluating the disease activity of ulcerative colitis (uc).", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "the aim of this study was to assess the concordance between the rachmilewitz endoscopic activity index ( eai ) and the harpaz histopathological activity scoring system ( hss) , which are used for evaluating the disease activity of ulcerative colitis ( uc ) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "in patients with ulcerative colitis suffering from arthritis a significant increase of disease activity ( rachmilewitz index ) could be shown as compared to ulcerative colitis patients without arthritis ( p < 0.02) .", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background: the accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "background\n\nthe accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (uc) according the rachmilewitz score is so far unknown.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "ulcerative colitis: correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "clinical activity in chron's disease was measured by crohn disease activity index and in ulcerative colitis patients by rachmilewitz endoscopic index.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "crohn's disease activity index and the rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "camrelizumab (shr-1210) is a humanised anti-programmed death-1 (anti pd-1) antibody.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "a tnfr2 3' flanking region polymorphism in systemic lupus erythematosus.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "knock-out of satb1 significantly inhibited cell viability and migration, and promoted schwann cells apoptosis.", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "long noncoding rna (lncrna, >200 nucleotides)", "telangiectasias are prominent small vessels (venules, capillaries or arterioles) that are visible as small red-purple focal lesions in the skin and mucous membranes.", "telangiectasias are prominent small vessels (venules, capillaries or arterioles) that are visible as small red-purple focal lesions in the skin and mucous membranes.", "to evaluate the clinical pk/pd of pth(1-34) delivered by a novel transdermal drug-coated microneedle patch system (zp-pth) for the treatment of osteoporosis.", "to evaluate the clinical pk/pd of pth(1-34) delivered by a novel transdermal drug-coated microneedle patch system (zp-pth) for the treatment of osteoporosis.", "to evaluate the clinical pk/pd of pth(1-34) delivered by a novel transdermal drug-coated microneedle patch system (zp-pth) for the treatment of osteoporosis.", "to evaluate the clinical pk/pd of pth(1-34) delivered by a novel transdermal drug-coated microneedle patch system (zp-pth) for the treatment of osteoporosis.", "to evaluate the clinical pk/pd of pth(1-34) delivered by a novel transdermal drug-coated microneedle patch system (zp-pth) for the treatment of osteoporosis.", "to evaluate the clinical pk/pd of pth(1-34) delivered by a novel transdermal drug-coated microneedle patch system (zp-pth) for the treatment of osteoporosis.", "to evaluate the clinical pk/pd of pth(1-34) delivered by a novel transdermal drug-coated microneedle patch system (zp-pth) for the treatment of osteoporosis.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "administration of senktide, highly potent and selective nk3r agonist, resulted in increase of serum lh concentration, induction of vms, increase in heart rate, and skin temperature in postmenopausal women.", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "tlr7 is encoded by an x chromosome locus, and we examined here whether the tlr7 gene evades silencing by x chromosome inactivation in immune cells from women and klinefelter syndrome males", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene tp53 and that the increase in tp53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive tp53 signaling pathway in the elephant (proboscidean) lineage.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction.", "while humans have 1 copy (2 alleles) of tp53, african elephants have at least 20 copies (40 alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription polymerase chain reaction."], "id": ["5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_0", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_1", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_2", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2f0afcfbd6abf43b000028_3", "5e2902e48b3851296d000006_4", "5e2902e48b3851296d000006_4", "5e2902e48b3851296d000006_4", "5e2902e48b3851296d000006_4", "5e2902e48b3851296d000006_4", "5e2902e48b3851296d000006_4", "5e2902e48b3851296d000006_4", "5e2902e48b3851296d000006_4", "5e2902e48b3851296d000006_5", "5e2902e48b3851296d000006_5", "5e2902e48b3851296d000006_5", "5e2902e48b3851296d000006_5", "5e2902e48b3851296d000006_5", "5e2902e48b3851296d000006_5", "5e2902e48b3851296d000006_5", "5e2902e48b3851296d000006_5", "5e2902e48b3851296d000006_6", "5e2902e48b3851296d000006_6", "5e2902e48b3851296d000006_6", "5e2902e48b3851296d000006_6", "5e2902e48b3851296d000006_6", "5e2902e48b3851296d000006_6", "5e2902e48b3851296d000006_6", "5e2902e48b3851296d000006_6", "5e2902e48b3851296d000006_7", "5e2902e48b3851296d000006_7", "5e2902e48b3851296d000006_7", "5e2902e48b3851296d000006_7", "5e2902e48b3851296d000006_7", "5e2902e48b3851296d000006_7", "5e2902e48b3851296d000006_7", "5e2902e48b3851296d000006_7", "5e2902e48b3851296d000006_8", "5e2902e48b3851296d000006_8", "5e2902e48b3851296d000006_8", "5e2902e48b3851296d000006_8", "5e2902e48b3851296d000006_8", "5e2902e48b3851296d000006_8", "5e2902e48b3851296d000006_8", "5e2902e48b3851296d000006_8", "5e2902e48b3851296d000006_9", "5e2902e48b3851296d000006_9", "5e2902e48b3851296d000006_9", "5e2902e48b3851296d000006_9", "5e2902e48b3851296d000006_9", "5e2902e48b3851296d000006_9", "5e2902e48b3851296d000006_9", "5e2902e48b3851296d000006_9", "5e2902e48b3851296d000006_10", "5e2902e48b3851296d000006_10", "5e2902e48b3851296d000006_10", "5e2902e48b3851296d000006_10", "5e2902e48b3851296d000006_10", "5e2902e48b3851296d000006_10", "5e2902e48b3851296d000006_10", "5e2902e48b3851296d000006_10", "5e2902e48b3851296d000006_11", "5e2902e48b3851296d000006_11", "5e2902e48b3851296d000006_11", "5e2902e48b3851296d000006_11", "5e2902e48b3851296d000006_11", "5e2902e48b3851296d000006_11", "5e2902e48b3851296d000006_11", "5e2902e48b3851296d000006_11", "5e2902e48b3851296d000006_12", "5e2902e48b3851296d000006_12", "5e2902e48b3851296d000006_12", "5e2902e48b3851296d000006_12", "5e2902e48b3851296d000006_12", "5e2902e48b3851296d000006_12", "5e2902e48b3851296d000006_12", "5e2902e48b3851296d000006_12", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_13", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_14", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_15", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_16", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_17", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_18", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_19", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_20", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5c74285c7c78d694710000a3_21", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_22", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_23", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_24", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e2b2c85fbd6abf43b000007_25", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_26", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_27", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5e3da25848dab47f26000004_28", "5d31b847b3a6380763000002_29", "5d31b847b3a6380763000002_29", "5d31b847b3a6380763000002_29", "5d31b847b3a6380763000002_29", "5d31b847b3a6380763000002_29", "5d31b847b3a6380763000002_29", "5d31b847b3a6380763000002_29", "5d31b847b3a6380763000002_29", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_30", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_31", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_32", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_33", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_34", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e4940f46d0a277941000004_35", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e31cceafbd6abf43b000052_36", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_37", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_38", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_39", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_40", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_41", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5e3c6c9eb5b409ea53000022_42", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_43", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5d387aa8a1e159510500000f_44", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_45", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_46", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_47", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_48", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_49", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_50", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_51", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_52", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_53", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_54", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5e31cbd4fbd6abf43b00004f_55", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5d35f1267bc3fee31f000004_56", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_57", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_58", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_59", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_60", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_61", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_62", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_63", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_64", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_65", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_66", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_67", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_68", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_69", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_70", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e460f823f54159529000006_71", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_72", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_73", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_74", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_75", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e4604d83f54159529000003_76", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_77", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_78", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_79", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_80", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_81", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_82", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_83", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_84", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_85", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_86", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_87", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_88", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e48a916d14c9f295d00000f_89", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e76452fc6a8763d23000015_90", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e5bafa01af46fc130000002_91", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e763bd4c6a8763d2300000f_92", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_93", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_94", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_95", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_96", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_97", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_98", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_99", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e2f4a8bfbd6abf43b00002a_100", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e35dc26158f994d3a000006_101", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_102", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_103", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_104", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_105", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_106", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_107", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_108", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_109", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e4601293f54159529000002_110", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e36cf8eb5b409ea53000007_111", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e6de3f21af46fc130000022_112", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_113", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_114", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_115", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_116", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_117", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_118", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e669e401af46fc13000001a_119", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_120", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_121", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e5e50751af46fc13000000b_122", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_123", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_124", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_125", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_126", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_127", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_128", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_129", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_130", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_131", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_132", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_133", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e47546d3f54159529000019_134", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5e4b540b6d0a27794100001c_135", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d386ed6a1e1595105000004_136", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5d36b8a37bc3fee31f000009_137", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e6e8f92c6a8763d23000004_138", "5e3c686fb5b409ea53000020_139", "5e3c686fb5b409ea53000020_139", "5e7f64d6835f4e477700001f_140", "5e7f64d6835f4e477700001f_140", "5e7f64d6835f4e477700001f_140", "5e7f64d6835f4e477700001f_140", "5e7f64d6835f4e477700001f_140", "5e7f64d6835f4e477700001f_140", "5e7f64d6835f4e477700001f_140", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5e5438c3b761aafe09000003_141", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d38767ca1e159510500000b_142", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_143", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144", "5d388535a1e1595105000018_144"], "question": ["which receptor is inhibited by tivozanib?", "[PAD] [PAD] what receptors does tivozanib inhibit?", "[PAD] [PAD] which receptor inhibits tivosanib?", "[PAD] [PAD] which receptor does tivozanib inhibit?", "[PAD] [PAD] which receptors does tivozanib inhibit?", "[PAD] [PAD] which receptor inhibits tivozanib?", "[PAD] which receptor is tivosanib inhibited?", "[PAD] what receptor is blocked by tivozanib?", "which receptor is inhibited by tivosanib?", "[PAD] [PAD] which tivozanib receptors prevent it?", "[PAD] which receptor is blocked by tivozanib?", "[PAD] [PAD] [PAD] what receptors inhibit tivozanib?", "[PAD] which receptors are blocked by tivozanib?", "[PAD] which receptors are blocked by tibozanib?", "which receptors is inhibited by tivosanib?", "[PAD] which receptor is blocked by tivosanib?", "which receptor is inhibited by thiozanib?", "[PAD] [PAD] what receptor does tivozanib inhibit?", "what receptor is inhibited by tivozanib?", "[PAD] which recipient is blocked by tivozanib?", "[PAD] which receptor is suppressed by tivosanib?", "which receptor is inhibited by tivozanib?", "[PAD] [PAD] what receptors does tivozanib inhibit?", "[PAD] [PAD] which receptor inhibits tivosanib?", "[PAD] [PAD] which receptor does tivozanib inhibit?", "[PAD] [PAD] which receptors does tivozanib inhibit?", "[PAD] [PAD] which receptor inhibits tivozanib?", "[PAD] which receptor is tivosanib inhibited?", "[PAD] what receptor is blocked by tivozanib?", "which receptor is inhibited by tivosanib?", "[PAD] [PAD] which tivozanib receptors prevent it?", "[PAD] which receptor is blocked by tivozanib?", "[PAD] [PAD] [PAD] what receptors inhibit tivozanib?", "[PAD] which receptors are blocked by tivozanib?", "[PAD] which receptors are blocked by tibozanib?", "which receptors is inhibited by tivosanib?", "[PAD] which receptor is blocked by tivosanib?", "which receptor is inhibited by thiozanib?", "[PAD] [PAD] what receptor does tivozanib inhibit?", "what receptor is inhibited by tivozanib?", "[PAD] which recipient is blocked by tivozanib?", "[PAD] which receptor is suppressed by tivosanib?", "which receptor is inhibited by tivozanib?", "[PAD] [PAD] what receptors does tivozanib inhibit?", "[PAD] [PAD] which receptor inhibits tivosanib?", "[PAD] [PAD] which receptor does tivozanib inhibit?", "[PAD] [PAD] which receptors does tivozanib inhibit?", "[PAD] [PAD] which receptor inhibits tivozanib?", "[PAD] which receptor is tivosanib inhibited?", "[PAD] what receptor is blocked by tivozanib?", "which receptor is inhibited by tivosanib?", "[PAD] [PAD] which tivozanib receptors prevent it?", "[PAD] which receptor is blocked by tivozanib?", "[PAD] [PAD] [PAD] what receptors inhibit tivozanib?", "[PAD] which receptors are blocked by tivozanib?", "[PAD] which receptors are blocked by tibozanib?", "which receptors is inhibited by tivosanib?", "[PAD] which receptor is blocked by tivosanib?", "which receptor is inhibited by thiozanib?", "[PAD] [PAD] what receptor does tivozanib inhibit?", "what receptor is inhibited by tivozanib?", "[PAD] which recipient is blocked by tivozanib?", "[PAD] which receptor is suppressed by tivosanib?", "which receptor is inhibited by tivozanib?", "[PAD] [PAD] what receptors does tivozanib inhibit?", "[PAD] [PAD] which receptor inhibits tivosanib?", "[PAD] [PAD] which receptor does tivozanib inhibit?", "[PAD] [PAD] which receptors does tivozanib inhibit?", "[PAD] [PAD] which receptor inhibits tivozanib?", "[PAD] which receptor is tivosanib inhibited?", "[PAD] what receptor is blocked by tivozanib?", "which receptor is inhibited by tivosanib?", "[PAD] [PAD] which tivozanib receptors prevent it?", "[PAD] which receptor is blocked by tivozanib?", "[PAD] [PAD] [PAD] what receptors inhibit tivozanib?", "[PAD] which receptors are blocked by tivozanib?", "[PAD] which receptors are blocked by tibozanib?", "which receptors is inhibited by tivosanib?", "[PAD] which receptor is blocked by tivosanib?", "which receptor is inhibited by thiozanib?", "[PAD] [PAD] what receptor does tivozanib inhibit?", "what receptor is inhibited by tivozanib?", "[PAD] which recipient is blocked by tivozanib?", "[PAD] which receptor is suppressed by tivosanib?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "which disease can be treated with anifrolumab?", "what disease can be treated with anifrolumab?", "what diseases can be treated with anifrolumab?", "[PAD] what disease can be treated with aniprolumab?", "[PAD] [PAD] what diseases can anifrolumab treat?", "which diseases can be treated with anifrolumab?", "[PAD] [PAD] [PAD] [PAD] what is anifrolumab?", "[PAD] what disease can be treated with anifrumab?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] in which cellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cellular compartment do voltage grains locate?", "[PAD] [PAD] [PAD] [PAD] in which cell division are the stress grains located?", "[PAD] [PAD] in which cellular segment are the stress granules localized?", "[PAD] [PAD] [PAD] [PAD] in which cell segment are the stress grains localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules localized?", "[PAD] [PAD] in which cell compartments are stress granules located?", "[PAD] [PAD] in which cell compartment are the stress granules localized?", "[PAD] [PAD] in which cell compartment are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules localized?", "[PAD] [PAD] [PAD] in which cellular space are stress granules located?", "[PAD] [PAD] in which cell compartment do stress granules localize?", "[PAD] [PAD] in which cell space are the stress granules located?", "[PAD] [PAD] [PAD] in which cellular compartment do the stress grains localize?", "[PAD] [PAD] in which cellular compartment are the stress granules located?", "[PAD] [PAD] in which cell part are the stress granules localized?", "[PAD] [PAD] [PAD] in which cell compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment are the stress grains located?", "[PAD] [PAD] [PAD] [PAD] in which cell are stress granules located?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell space are stress grains localized?", "[PAD] [PAD] [PAD] [PAD] in which cell compartments are stress cells located?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cellular compartment contains stress granules?", "in which intracellular compartment do stress granules localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress details localized?", "[PAD] [PAD] in which cell compartment are the stress granules found?", "[PAD] [PAD] [PAD] in which cellular space do stress granules locate?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cell part are stress seeds located?", "[PAD] in which compartment of the cell are stress granules localized?", "[PAD] [PAD] [PAD] in which cell region are stress granules localized?", "[PAD] [PAD] in what part of the cell are the stress cells located?", "[PAD] in what part of the cell are the stress granules?", "[PAD] [PAD] [PAD] in which cellular compartment are stress granules located?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment are the stress particles localized?", "[PAD] [PAD] [PAD] in which compartment of the cell are stress particles located?", "[PAD] [PAD] [PAD] [PAD] in which cell compartment do stress particles localize?", "[PAD] [PAD] [PAD] [PAD] in which cellular compartment localized pressure granules?", "[PAD] [PAD] which disease can be classified using the koos classification?", "[PAD] [PAD] what disease can be classified using the koos classification?", "[PAD] [PAD] [PAD] what disease can be classified using coose classification?", "[PAD] [PAD] [PAD] which disease can be classified by koos classification?", "[PAD] [PAD] [PAD] what diseases can be classified using koos classification?", "[PAD] [PAD] what disease can be classified using the kusa classification?", "[PAD] [PAD] which disease can be classified by the koos classification?", "[PAD] [PAD] [PAD] what disease can be classified using koos classification?", "[PAD] [PAD] which diseases can be classified using the koos classification?", "[PAD] [PAD] which disease can be classified with the koos classification?", "[PAD] [PAD] [PAD] what diseases can be classified together using the classification?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified using koos?", "[PAD] [PAD] what diseases can be classified using the koos classification?", "[PAD] [PAD] [PAD] which disease can be classified by kus classification?", "[PAD] which disease can be classified using the cohesive classification?", "[PAD] [PAD] what disease can be classified with the koos classification?", "[PAD] [PAD] what disease can be classified by using koos classification?", "[PAD] [PAD] [PAD] which diseases can be classified using koos classification?", "what diseases can be classified according to the kohs classification?", "[PAD] [PAD] [PAD] what disease can be diagnosed using koos classification?", "what disease can be classified according to the classification of kusa?", "[PAD] [PAD] [PAD] which disease can be classified using kos classification?", "[PAD] what diseases can be classified using the koos taxonomy?", "[PAD] [PAD] [PAD] what disease can be classified using koos distribution?", "[PAD] [PAD] which disease can be classified using the koos classification?", "[PAD] [PAD] what disease can be classified using the koos classification?", "[PAD] [PAD] [PAD] what disease can be classified using coose classification?", "[PAD] [PAD] [PAD] which disease can be classified by koos classification?", "[PAD] [PAD] [PAD] what diseases can be classified using koos classification?", "[PAD] [PAD] what disease can be classified using the kusa classification?", "[PAD] [PAD] which disease can be classified by the koos classification?", "[PAD] [PAD] [PAD] what disease can be classified using koos classification?", "[PAD] [PAD] which diseases can be classified using the koos classification?", "[PAD] [PAD] which disease can be classified with the koos classification?", "[PAD] [PAD] [PAD] what diseases can be classified together using the classification?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified using koos?", "[PAD] [PAD] what diseases can be classified using the koos classification?", "[PAD] [PAD] [PAD] which disease can be classified by kus classification?", "[PAD] which disease can be classified using the cohesive classification?", "[PAD] [PAD] what disease can be classified with the koos classification?", "[PAD] [PAD] what disease can be classified by using koos classification?", "[PAD] [PAD] [PAD] which diseases can be classified using koos classification?", "what diseases can be classified according to the kohs classification?", "[PAD] [PAD] [PAD] what disease can be diagnosed using koos classification?", "what disease can be classified according to the classification of kusa?", "[PAD] [PAD] [PAD] which disease can be classified using kos classification?", "[PAD] what diseases can be classified using the koos taxonomy?", "[PAD] [PAD] [PAD] what disease can be classified using koos distribution?", "[PAD] [PAD] which disease can be classified using the koos classification?", "[PAD] [PAD] what disease can be classified using the koos classification?", "[PAD] [PAD] [PAD] what disease can be classified using coose classification?", "[PAD] [PAD] [PAD] which disease can be classified by koos classification?", "[PAD] [PAD] [PAD] what diseases can be classified using koos classification?", "[PAD] [PAD] what disease can be classified using the kusa classification?", "[PAD] [PAD] which disease can be classified by the koos classification?", "[PAD] [PAD] [PAD] what disease can be classified using koos classification?", "[PAD] [PAD] which diseases can be classified using the koos classification?", "[PAD] [PAD] which disease can be classified with the koos classification?", "[PAD] [PAD] [PAD] what diseases can be classified together using the classification?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified using koos?", "[PAD] [PAD] what diseases can be classified using the koos classification?", "[PAD] [PAD] [PAD] which disease can be classified by kus classification?", "[PAD] which disease can be classified using the cohesive classification?", "[PAD] [PAD] what disease can be classified with the koos classification?", "[PAD] [PAD] what disease can be classified by using koos classification?", "[PAD] [PAD] [PAD] which diseases can be classified using koos classification?", "what diseases can be classified according to the kohs classification?", "[PAD] [PAD] [PAD] what disease can be diagnosed using koos classification?", "what disease can be classified according to the classification of kusa?", "[PAD] [PAD] [PAD] which disease can be classified using kos classification?", "[PAD] what diseases can be classified using the koos taxonomy?", "[PAD] [PAD] [PAD] what disease can be classified using koos distribution?", "[PAD] [PAD] which disease can be classified using the koos classification?", "[PAD] [PAD] what disease can be classified using the koos classification?", "[PAD] [PAD] [PAD] what disease can be classified using coose classification?", "[PAD] [PAD] [PAD] which disease can be classified by koos classification?", "[PAD] [PAD] [PAD] what diseases can be classified using koos classification?", "[PAD] [PAD] what disease can be classified using the kusa classification?", "[PAD] [PAD] which disease can be classified by the koos classification?", "[PAD] [PAD] [PAD] what disease can be classified using koos classification?", "[PAD] [PAD] which diseases can be classified using the koos classification?", "[PAD] [PAD] which disease can be classified with the koos classification?", "[PAD] [PAD] [PAD] what diseases can be classified together using the classification?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified using koos?", "[PAD] [PAD] what diseases can be classified using the koos classification?", "[PAD] [PAD] [PAD] which disease can be classified by kus classification?", "[PAD] which disease can be classified using the cohesive classification?", "[PAD] [PAD] what disease can be classified with the koos classification?", "[PAD] [PAD] what disease can be classified by using koos classification?", "[PAD] [PAD] [PAD] which diseases can be classified using koos classification?", "what diseases can be classified according to the kohs classification?", "[PAD] [PAD] [PAD] what disease can be diagnosed using koos classification?", "what disease can be classified according to the classification of kusa?", "[PAD] [PAD] [PAD] which disease can be classified using kos classification?", "[PAD] what diseases can be classified using the koos taxonomy?", "[PAD] [PAD] [PAD] what disease can be classified using koos distribution?", "[PAD] what rare disease is associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] which rare disease is associated with a mutation in the gpc6 gene on chromosome 13?", "what is a rare disease associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] what is the rare disease with a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare diseases are associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] which rare disease is linked to a mutation in the gpc6 gene on chromosome 13?", "[PAD] what rare diseases are associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] which rare disease is associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] what rare disease is the mutation in the gpc6 gene on chromosome 13 associated with?", "[PAD] what rare disease is related to a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare disease is associated with mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] [PAD] what rare disease is associated with a gpc6 gene mutation on chromosome 13?", "[PAD] what are the rare diseases associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] what is the rare disease associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare disease is associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] what rare disease is associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] which rare disease is associated with a mutation in the gpc6 gene on chromosome 13?", "what is a rare disease associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] what is the rare disease with a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare diseases are associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] which rare disease is linked to a mutation in the gpc6 gene on chromosome 13?", "[PAD] what rare diseases are associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] which rare disease is associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] what rare disease is the mutation in the gpc6 gene on chromosome 13 associated with?", "[PAD] what rare disease is related to a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare disease is associated with mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] [PAD] what rare disease is associated with a gpc6 gene mutation on chromosome 13?", "[PAD] what are the rare diseases associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] what is the rare disease associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare disease is associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] what rare disease is associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] which rare disease is associated with a mutation in the gpc6 gene on chromosome 13?", "what is a rare disease associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] what is the rare disease with a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare diseases are associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] which rare disease is linked to a mutation in the gpc6 gene on chromosome 13?", "[PAD] what rare diseases are associated with a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] which rare disease is associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] what rare disease is the mutation in the gpc6 gene on chromosome 13 associated with?", "[PAD] what rare disease is related to a mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare disease is associated with mutation in the gpc6 gene on chromosome 13?", "[PAD] [PAD] [PAD] what rare disease is associated with a gpc6 gene mutation on chromosome 13?", "[PAD] what are the rare diseases associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] what is the rare disease associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] [PAD] what rare disease is associated with mutations in the gpc6 gene on chromosome 13?", "[PAD] how many genes belong to the krab-znf family in the human genome?", "how many genes belonging to the krab-znf family are in the human genome?", "[PAD] how many genes in the human genome belong to the krab-znf family?", "how many genes are part of the krab-znf family in the human genome?", "how many genes are related to the krab-znf family in the human genome?", "[PAD] how many genes belong to the krab-znf family of the human genome?", "[PAD] how many genes are in the krab-znf family in the human genome?", "how many genes of the krab-znf family are there in the human genome?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many canned human lncrnas come from ancestral genes encoding proteins?", "[PAD] how many conserved human lncrnas are annotated that come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many known conserved human lncrnas are derived from genes encoding ancestral proteins?", "how much of the annotated canned human lncrna comes from ancestral protein-encoding genes?", "[PAD] [PAD] how much conserved human lncrna has been commented on from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas are derived from genes encoding ancestral protein?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from genes encoding ancestral proteins?", "[PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] how many labeled conserved human lncrnas come from genes that encode ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor genes encoding proteins?", "[PAD] [PAD] how many annotated, conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas are from genes encoding ancestral proteins?", "[PAD] how many annotated conserved human lncrnas are derived from the genes encoding the ancestral protein?", "[PAD] [PAD] how many annotated and conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] how many annotated canned human lncrnas come from the ancestor protein encoding gene?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral genes encoding proteins?", "[PAD] [PAD] how many conserved human lncrnas are annotated from genes that encode ancestral proteins?", "[PAD] how many canned canned human lncrnas come from ancient protein-encoding genes?", "[PAD] how many annotated, conserved human lncrnas are derived from genes encoding an ancient protein?", "[PAD] [PAD] [PAD] [PAD] how many labeled preserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] how many annotated human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how much annotated conserved human lncrna comes from ancestor protein-coded genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] are annotated conserved human lncrnas derived from genes encoding proteins of ancestors?", "[PAD] [PAD] how much of the annotated conserved human lncrna comes from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many observed conserved human lncrnas are derived from ancestor protein coding genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein -encoding genes?", "[PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes that encode proteins?", "[PAD] [PAD] [PAD] [PAD] how many protected human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] [PAD] how many labeled preserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor-encoding protein genes?", "[PAD] [PAD] [PAD] [PAD] how many stored human lncrnas are derived from ancestral protein synthesis genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many defined safe human lncrnas come from native protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human increments come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many canned human lncrnas come from ancestral genes encoding proteins?", "[PAD] how many conserved human lncrnas are annotated that come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many known conserved human lncrnas are derived from genes encoding ancestral proteins?", "how much of the annotated canned human lncrna comes from ancestral protein-encoding genes?", "[PAD] [PAD] how much conserved human lncrna has been commented on from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas are derived from genes encoding ancestral protein?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from genes encoding ancestral proteins?", "[PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] how many labeled conserved human lncrnas come from genes that encode ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor genes encoding proteins?", "[PAD] [PAD] how many annotated, conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas are from genes encoding ancestral proteins?", "[PAD] how many annotated conserved human lncrnas are derived from the genes encoding the ancestral protein?", "[PAD] [PAD] how many annotated and conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] how many annotated canned human lncrnas come from the ancestor protein encoding gene?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral genes encoding proteins?", "[PAD] [PAD] how many conserved human lncrnas are annotated from genes that encode ancestral proteins?", "[PAD] how many canned canned human lncrnas come from ancient protein-encoding genes?", "[PAD] how many annotated, conserved human lncrnas are derived from genes encoding an ancient protein?", "[PAD] [PAD] [PAD] [PAD] how many labeled preserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] how many annotated human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how much annotated conserved human lncrna comes from ancestor protein-coded genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] are annotated conserved human lncrnas derived from genes encoding proteins of ancestors?", "[PAD] [PAD] how much of the annotated conserved human lncrna comes from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many observed conserved human lncrnas are derived from ancestor protein coding genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein -encoding genes?", "[PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes that encode proteins?", "[PAD] [PAD] [PAD] [PAD] how many protected human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] [PAD] how many labeled preserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor-encoding protein genes?", "[PAD] [PAD] [PAD] [PAD] how many stored human lncrnas are derived from ancestral protein synthesis genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many defined safe human lncrnas come from native protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human increments come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many canned human lncrnas come from ancestral genes encoding proteins?", "[PAD] how many conserved human lncrnas are annotated that come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many known conserved human lncrnas are derived from genes encoding ancestral proteins?", "how much of the annotated canned human lncrna comes from ancestral protein-encoding genes?", "[PAD] [PAD] how much conserved human lncrna has been commented on from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas are derived from genes encoding ancestral protein?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from genes encoding ancestral proteins?", "[PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] how many labeled conserved human lncrnas come from genes that encode ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor genes encoding proteins?", "[PAD] [PAD] how many annotated, conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas are from genes encoding ancestral proteins?", "[PAD] how many annotated conserved human lncrnas are derived from the genes encoding the ancestral protein?", "[PAD] [PAD] how many annotated and conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] how many annotated canned human lncrnas come from the ancestor protein encoding gene?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral genes encoding proteins?", "[PAD] [PAD] how many conserved human lncrnas are annotated from genes that encode ancestral proteins?", "[PAD] how many canned canned human lncrnas come from ancient protein-encoding genes?", "[PAD] how many annotated, conserved human lncrnas are derived from genes encoding an ancient protein?", "[PAD] [PAD] [PAD] [PAD] how many labeled preserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] how many annotated human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how much annotated conserved human lncrna comes from ancestor protein-coded genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] are annotated conserved human lncrnas derived from genes encoding proteins of ancestors?", "[PAD] [PAD] how much of the annotated conserved human lncrna comes from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many observed conserved human lncrnas are derived from ancestor protein coding genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein -encoding genes?", "[PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes that encode proteins?", "[PAD] [PAD] [PAD] [PAD] how many protected human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] [PAD] how many labeled preserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor-encoding protein genes?", "[PAD] [PAD] [PAD] [PAD] how many stored human lncrnas are derived from ancestral protein synthesis genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many defined safe human lncrnas come from native protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human increments come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many canned human lncrnas come from ancestral genes encoding proteins?", "[PAD] how many conserved human lncrnas are annotated that come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many known conserved human lncrnas are derived from genes encoding ancestral proteins?", "how much of the annotated canned human lncrna comes from ancestral protein-encoding genes?", "[PAD] [PAD] how much conserved human lncrna has been commented on from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas are derived from genes encoding ancestral protein?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from genes encoding ancestral proteins?", "[PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] how many labeled conserved human lncrnas come from genes that encode ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor genes encoding proteins?", "[PAD] [PAD] how many annotated, conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas are from genes encoding ancestral proteins?", "[PAD] how many annotated conserved human lncrnas are derived from the genes encoding the ancestral protein?", "[PAD] [PAD] how many annotated and conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] how many annotated canned human lncrnas come from the ancestor protein encoding gene?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral genes encoding proteins?", "[PAD] [PAD] how many conserved human lncrnas are annotated from genes that encode ancestral proteins?", "[PAD] how many canned canned human lncrnas come from ancient protein-encoding genes?", "[PAD] how many annotated, conserved human lncrnas are derived from genes encoding an ancient protein?", "[PAD] [PAD] [PAD] [PAD] how many labeled preserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] how many annotated human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how much annotated conserved human lncrna comes from ancestor protein-coded genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] are annotated conserved human lncrnas derived from genes encoding proteins of ancestors?", "[PAD] [PAD] how much of the annotated conserved human lncrna comes from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many observed conserved human lncrnas are derived from ancestor protein coding genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein -encoding genes?", "[PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes that encode proteins?", "[PAD] [PAD] [PAD] [PAD] how many protected human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] [PAD] how many labeled preserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor-encoding protein genes?", "[PAD] [PAD] [PAD] [PAD] how many stored human lncrnas are derived from ancestral protein synthesis genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many defined safe human lncrnas come from native protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human increments come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many canned human lncrnas come from ancestral genes encoding proteins?", "[PAD] how many conserved human lncrnas are annotated that come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many known conserved human lncrnas are derived from genes encoding ancestral proteins?", "how much of the annotated canned human lncrna comes from ancestral protein-encoding genes?", "[PAD] [PAD] how much conserved human lncrna has been commented on from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas are derived from genes encoding ancestral protein?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from genes encoding ancestral proteins?", "[PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] how many labeled conserved human lncrnas come from genes that encode ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor genes encoding proteins?", "[PAD] [PAD] how many annotated, conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas are from genes encoding ancestral proteins?", "[PAD] how many annotated conserved human lncrnas are derived from the genes encoding the ancestral protein?", "[PAD] [PAD] how many annotated and conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] how many annotated canned human lncrnas come from the ancestor protein encoding gene?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral genes encoding proteins?", "[PAD] [PAD] how many conserved human lncrnas are annotated from genes that encode ancestral proteins?", "[PAD] how many canned canned human lncrnas come from ancient protein-encoding genes?", "[PAD] how many annotated, conserved human lncrnas are derived from genes encoding an ancient protein?", "[PAD] [PAD] [PAD] [PAD] how many labeled preserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] how many annotated human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how much annotated conserved human lncrna comes from ancestor protein-coded genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] are annotated conserved human lncrnas derived from genes encoding proteins of ancestors?", "[PAD] [PAD] how much of the annotated conserved human lncrna comes from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many observed conserved human lncrnas are derived from ancestor protein coding genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein -encoding genes?", "[PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes that encode proteins?", "[PAD] [PAD] [PAD] [PAD] how many protected human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] [PAD] how many labeled preserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor-encoding protein genes?", "[PAD] [PAD] [PAD] [PAD] how many stored human lncrnas are derived from ancestral protein synthesis genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many defined safe human lncrnas come from native protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human increments come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many canned human lncrnas come from ancestral genes encoding proteins?", "[PAD] how many conserved human lncrnas are annotated that come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how many known conserved human lncrnas are derived from genes encoding ancestral proteins?", "how much of the annotated canned human lncrna comes from ancestral protein-encoding genes?", "[PAD] [PAD] how much conserved human lncrna has been commented on from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas are derived from genes encoding ancestral protein?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from genes encoding ancestral proteins?", "[PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] how many labeled conserved human lncrnas come from genes that encode ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor genes encoding proteins?", "[PAD] [PAD] how many annotated, conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas are from genes encoding ancestral proteins?", "[PAD] how many annotated conserved human lncrnas are derived from the genes encoding the ancestral protein?", "[PAD] [PAD] how many annotated and conserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] how many annotated canned human lncrnas come from the ancestor protein encoding gene?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from ancestral genes encoding proteins?", "[PAD] [PAD] how many conserved human lncrnas are annotated from genes that encode ancestral proteins?", "[PAD] how many canned canned human lncrnas come from ancient protein-encoding genes?", "[PAD] how many annotated, conserved human lncrnas are derived from genes encoding an ancient protein?", "[PAD] [PAD] [PAD] [PAD] how many labeled preserved human lncrnas come from ancestral protein coding genes?", "[PAD] [PAD] [PAD] how many annotated human lncrnas are derived from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] how much annotated conserved human lncrna comes from ancestor protein-coded genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] [PAD] are annotated conserved human lncrnas derived from genes encoding proteins of ancestors?", "[PAD] [PAD] how much of the annotated conserved human lncrna comes from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many observed conserved human lncrnas are derived from ancestor protein coding genes?", "[PAD] [PAD] [PAD] how many annotated preserved human lncrnas come from ancestral protein -encoding genes?", "[PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes that encode proteins?", "[PAD] [PAD] [PAD] [PAD] how many protected human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestral genes encoding proteins?", "[PAD] [PAD] [PAD] how many labeled preserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas come from ancestor-encoding protein genes?", "[PAD] [PAD] [PAD] [PAD] how many stored human lncrnas are derived from ancestral protein synthesis genes?", "[PAD] [PAD] [PAD] how many annotated conserved human lncrnas are derived from genes encoding ancestral proteins?", "[PAD] [PAD] [PAD] [PAD] how many defined safe human lncrnas come from native protein coding genes?", "[PAD] [PAD] [PAD] [PAD] how many annotated conserved human increments come from ancestral protein-coding genes?", "[PAD] [PAD] [PAD] what is the chromosomal location of the ldl receptor gene associated with autosomal dominant familial hypercholesterolemia?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosomal locus of the ldl receptor gene associated with autosomal dominant hypercholesterolemia?", "[PAD] [PAD] [PAD] what is the chromosomal position of the ldl receptor gene associated with autosomal dominant familial hypercholesterolemia?", "[PAD] [PAD] [PAD] what is the chromosomal location of the ldl receptor gene associated with major autosomal familial hypercholesterolemia?", "[PAD] [PAD] [PAD] [PAD] what chromosomal location of the ldl receptor gene is associated with autosomal dominant familial hypercholesterolemia?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where are the chromosomes of ldl receptor genes associated with autosomal dominant familial hypercholesterolemia?", "[PAD] [PAD] [PAD] what is the chromosomal location of the ldl receptor gene associated with dominant autosomal familial hypercholesterolemia?", "[PAD] [PAD] what is the chromosome status of the ldl receptor gene that is associated with the self-regulating familial hypercholesterolaemia?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the ldl receptor gene associated with autosomal dominant hypercholesterolaemia?", "[PAD] [PAD] [PAD] what is the chromosomal location of the ldl receptor gene involved in autosomal dominant familial hypercholesterolemia?", "[PAD] [PAD] what is the chromosomal location of the ldl receptor gene associated with autosomal dominant familial hypercholesterolaemia?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the ldl receptor gene associated with autosomal dominant hypercholesterolemia?", "[PAD] what is the chromosomal localization of the ldl receptor gene associated with autosomal dominant familial hypercholesterolaemia?", "[PAD] [PAD] what is the chromosomal localization of the ldl receptor gene associated with autosomal dominant familial hypercholesterolemia?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the ldl receptor gene associated with autosomal family hypercholesterolemia?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the ldl receptor gene associated with autosomal dominant familial hypercholesterolemia?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the autosomal dominant hypercholesterolemia ldl receptor gene?", "what is the chromosomal location of the ldl receptor gene associated with autosomal dominant familial hypocholesterolemia?", "[PAD] what bacteria is associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] which bacteria are associated with stomach cancer and peptic ulcers?", "what are the bacteria associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer \u0565\u057a peptic ulcer?", "[PAD] [PAD] [PAD] what bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] what bacteria are present in gastric cancer and peptic ulcer?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcer disease?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcers?", "[PAD] what bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] which bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] [PAD] [PAD] what bacteria are associated with stomach cancer and ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] which bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] which bacterium is associated with gastric cancer and peptic ulcers?", "[PAD] what bacteria are linked to stomach cancer and peptic ulcers?", "[PAD] [PAD] which bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] [PAD] which bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] which bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] [PAD] what are the bacteria associated with gastric cancer and gastric ulcer?", "[PAD] what bacteria are involved in stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are involved in stomach cancer and stomach ulcers?", "[PAD] [PAD] which bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] which bacteria are associated with stomach cancer and peptic ulcers?", "what are the bacteria associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer \u0565\u057a peptic ulcer?", "[PAD] [PAD] [PAD] what bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] what bacteria are present in gastric cancer and peptic ulcer?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcer disease?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcers?", "[PAD] what bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] which bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] [PAD] [PAD] what bacteria are associated with stomach cancer and ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] which bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] which bacterium is associated with gastric cancer and peptic ulcers?", "[PAD] what bacteria are linked to stomach cancer and peptic ulcers?", "[PAD] [PAD] which bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] [PAD] which bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] which bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] [PAD] what are the bacteria associated with gastric cancer and gastric ulcer?", "[PAD] what bacteria are involved in stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are involved in stomach cancer and stomach ulcers?", "[PAD] [PAD] which bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] which bacteria are associated with stomach cancer and peptic ulcers?", "what are the bacteria associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer \u0565\u057a peptic ulcer?", "[PAD] [PAD] [PAD] what bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] what bacteria are present in gastric cancer and peptic ulcer?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcer disease?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcers?", "[PAD] what bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] which bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] [PAD] [PAD] what bacteria are associated with stomach cancer and ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] which bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] which bacterium is associated with gastric cancer and peptic ulcers?", "[PAD] what bacteria are linked to stomach cancer and peptic ulcers?", "[PAD] [PAD] which bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] [PAD] which bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] which bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] [PAD] what are the bacteria associated with gastric cancer and gastric ulcer?", "[PAD] what bacteria are involved in stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are involved in stomach cancer and stomach ulcers?", "[PAD] [PAD] which bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] which bacteria are associated with stomach cancer and peptic ulcers?", "what are the bacteria associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer \u0565\u057a peptic ulcer?", "[PAD] [PAD] [PAD] what bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] what bacteria are present in gastric cancer and peptic ulcer?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcer disease?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcers?", "[PAD] what bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] which bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] [PAD] [PAD] what bacteria are associated with stomach cancer and ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] which bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] which bacterium is associated with gastric cancer and peptic ulcers?", "[PAD] what bacteria are linked to stomach cancer and peptic ulcers?", "[PAD] [PAD] which bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] [PAD] which bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] which bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] [PAD] what are the bacteria associated with gastric cancer and gastric ulcer?", "[PAD] what bacteria are involved in stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are involved in stomach cancer and stomach ulcers?", "[PAD] [PAD] which bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] which bacteria are associated with stomach cancer and peptic ulcers?", "what are the bacteria associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer \u0565\u057a peptic ulcer?", "[PAD] [PAD] [PAD] what bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] what bacteria are present in gastric cancer and peptic ulcer?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcer disease?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcers?", "[PAD] what bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] which bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] [PAD] [PAD] what bacteria are associated with stomach cancer and ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] which bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] which bacterium is associated with gastric cancer and peptic ulcers?", "[PAD] what bacteria are linked to stomach cancer and peptic ulcers?", "[PAD] [PAD] which bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] [PAD] which bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] which bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] [PAD] what are the bacteria associated with gastric cancer and gastric ulcer?", "[PAD] what bacteria are involved in stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are involved in stomach cancer and stomach ulcers?", "[PAD] [PAD] which bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] which bacteria are associated with stomach cancer and peptic ulcers?", "what are the bacteria associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer \u0565\u057a peptic ulcer?", "[PAD] [PAD] [PAD] what bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] what bacteria are present in gastric cancer and peptic ulcer?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcer disease?", "[PAD] what bacteria are associated with stomach cancer and peptic ulcers?", "[PAD] what bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] which bacteria are associated with stomach cancer and stomach ulcers?", "[PAD] [PAD] [PAD] what bacteria are associated with stomach cancer and ulcers?", "[PAD] [PAD] what bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] which bacteria are associated with gastric cancer and peptic ulcers?", "[PAD] which bacterium is associated with gastric cancer and peptic ulcers?", "[PAD] what bacteria are linked to stomach cancer and peptic ulcers?", "[PAD] [PAD] which bacteria are associated with stomach cancer and peptic ulcer?", "[PAD] [PAD] [PAD] which bacteria are associated with gastric cancer and gastric ulcer?", "[PAD] [PAD] which bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] [PAD] what are the bacteria associated with gastric cancer and gastric ulcer?", "[PAD] what bacteria are involved in stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria is associated with gastric cancer and peptic ulcer?", "[PAD] what bacteria is associated with stomach cancer and peptic ulcers?", "[PAD] [PAD] what bacteria are involved in stomach cancer and stomach ulcers?", "[PAD] [PAD] which bacteria are associated with gastric cancer and peptic ulcer?", "[PAD] what is the purpose of the 123 dihydrorhodamine assay?", "[PAD] what is the purpose of the 123 dihydrodamine test?", "[PAD] [PAD] what is the purpose of dihydrodamine 123 analysis?", "[PAD] what is the purpose of the 123 dihydrorhodamine test?", "[PAD] [PAD] 123 what is the purpose of dihydrorodamine analysis?", "what is the purpose of the 123 dihydrododamine test?", "[PAD] [PAD] what is the purpose of 123 dihydrorodamine assay?", "[PAD] [PAD] what is the purpose of 123 dihydrorodamine analysis?", "[PAD] [PAD] 123 what is the purpose of dihydrorhodamine detection?", "[PAD] what is the purpose of the 123 dihydrorodamine test?", "what is the purpose of the determination of 123 dihydrorhodamine?", "what is the purpose of the 123-dihydrorhodamine assay?", "[PAD] [PAD] what is the purpose of 123 dihydrorhodamine assay?", "[PAD] [PAD] what is the 123 dihydrorhodamine assay used for?", "[PAD] [PAD] what is the purpose of 123 dihydrodamine analysis?", "[PAD] [PAD] what is the purpose of 123 dihydrorhodamine test?", "[PAD] 123 what is the purpose of the dihydrorhodamine assay?", "[PAD] what is the purpose of the 123 dihydrorhodamine evaluation?", "[PAD] what is the purpose of the 123 dihydrorhodamine study?", "what is the purpose of the analysis of 123 dihydrodamine?", "[PAD] what is the purpose of measuring 123 dihydroderodamine?", "[PAD] what is the purpose of the 123 dihydrorhodamine trial?", "what is the purpose of the analysis of 123 dihydrorodamine?", "[PAD] 123 what is the purpose of the dihydrorhodamine test?", "[PAD] what is the purpose of the 123 dihydrorodamine assay?", "[PAD] what is the purpose of the 123 dihydrorhodamine assay?", "[PAD] what is the purpose of the 123 dihydrodamine test?", "[PAD] [PAD] what is the purpose of dihydrodamine 123 analysis?", "[PAD] what is the purpose of the 123 dihydrorhodamine test?", "[PAD] [PAD] 123 what is the purpose of dihydrorodamine analysis?", "what is the purpose of the 123 dihydrododamine test?", "[PAD] [PAD] what is the purpose of 123 dihydrorodamine assay?", "[PAD] [PAD] what is the purpose of 123 dihydrorodamine analysis?", "[PAD] [PAD] 123 what is the purpose of dihydrorhodamine detection?", "[PAD] what is the purpose of the 123 dihydrorodamine test?", "what is the purpose of the determination of 123 dihydrorhodamine?", "what is the purpose of the 123-dihydrorhodamine assay?", "[PAD] [PAD] what is the purpose of 123 dihydrorhodamine assay?", "[PAD] [PAD] what is the 123 dihydrorhodamine assay used for?", "[PAD] [PAD] what is the purpose of 123 dihydrodamine analysis?", "[PAD] [PAD] what is the purpose of 123 dihydrorhodamine test?", "[PAD] 123 what is the purpose of the dihydrorhodamine assay?", "[PAD] what is the purpose of the 123 dihydrorhodamine evaluation?", "[PAD] what is the purpose of the 123 dihydrorhodamine study?", "what is the purpose of the analysis of 123 dihydrodamine?", "[PAD] what is the purpose of measuring 123 dihydroderodamine?", "[PAD] what is the purpose of the 123 dihydrorhodamine trial?", "what is the purpose of the analysis of 123 dihydrorodamine?", "[PAD] 123 what is the purpose of the dihydrorhodamine test?", "[PAD] what is the purpose of the 123 dihydrorodamine assay?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominate or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by dominant or recessive genes?", "[PAD] [PAD] [PAD] is it a dominant or recessive gene caused by huntington's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or residual gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recessive youth?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or subordinate gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington\u2019s disease caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominated or recessive gene?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a genetic predisposition?", "is huntington's disease caused by an obsessive gene or a recessive gene?", "[PAD] [PAD] [PAD] [PAD] huntington's disease is caused by a dominant or recessive gene?", "[PAD] [PAD] [PAD] [PAD] is huntington's disease caused by a dominant or recurrent gene?", "which is the effect of the hp1a protein on chromatin?", "what is the effect of the hp1a protein on chromatin?", "[PAD] what is the effect of hp1a protein on chromatin?", "[PAD] [PAD] [PAD] what effect does hp1a have on chromatin?", "[PAD] [PAD] [PAD] [PAD] how does hp1a protein affect chromatin?", "[PAD] what effect does the hp1a protein have on chromatin?", "[PAD] [PAD] what is the effect of hp1a on chromatin?", "[PAD] which effect does the hp1a protein have on chromatin?", "[PAD] [PAD] what effect does hp1a protein have on chromatin?", "[PAD] [PAD] [PAD] what is the effect of hp1a protein on chromosome?", "[PAD] what effect does the protein hp1a have on chromatin?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "what is the target of galcanezumab?", "what is the goal of galcanezumab?", "[PAD] [PAD] [PAD] what is the target of shielding?", "what is the purpose of galcanezumaba?", "what is the target of galconezumab?", "[PAD] what is the purpose of galcanesumab?", "what is the purpose of galcanezumab?", "what is the target of gacizumab?", "what is the goal of galkanezumab?", "what is the target of galkanetsumab?", "what is the target of galkanezumab?", "what is the target of garkanezumab?", "what is the purpose of galkanezumab?", "[PAD] [PAD] what is galcanesumab aimed at?", "[PAD] which disease was studied in the cadiss trial?", "[PAD] what disease was studied in the cadiss trial?", "[PAD] which disease was studied in the cadiss test?", "[PAD] [PAD] which disease was tested in cadiss trials?", "[PAD] what disease was examined in the cadiss trial?", "[PAD] what disease was studied in the cadiss study?", "[PAD] which disease was studied in the cadiss study?", "[PAD] [PAD] what disease was the cadiss trial studied?", "[PAD] what disease was investigated in the cadiss study?", "[PAD] [PAD] [PAD] what disease was studied in cadiss?", "[PAD] what diseases were studied in the cadiss trial?", "what disease has been studied in the cadiss trial?", "[PAD] which diseases were studied in the cadiss trial?", "[PAD] what diseases were studied in the cadiss exam?", "[PAD] which disease was investigated in the cadiss trial?", "[PAD] what disease was studied in the cadis trial?", "[PAD] what disease was examined in the cadiss study?", "[PAD] [PAD] which disease was studied in cadiss trial?", "[PAD] what disease is studied in the cadiss process?", "[PAD] which disease was studied in the cadiss trial?", "[PAD] what disease was studied in the cadiss trial?", "[PAD] which disease was studied in the cadiss test?", "[PAD] [PAD] which disease was tested in cadiss trials?", "[PAD] what disease was examined in the cadiss trial?", "[PAD] what disease was studied in the cadiss study?", "[PAD] which disease was studied in the cadiss study?", "[PAD] [PAD] what disease was the cadiss trial studied?", "[PAD] what disease was investigated in the cadiss study?", "[PAD] [PAD] [PAD] what disease was studied in cadiss?", "[PAD] what diseases were studied in the cadiss trial?", "what disease has been studied in the cadiss trial?", "[PAD] which diseases were studied in the cadiss trial?", "[PAD] what diseases were studied in the cadiss exam?", "[PAD] which disease was investigated in the cadiss trial?", "[PAD] what disease was studied in the cadis trial?", "[PAD] what disease was examined in the cadiss study?", "[PAD] [PAD] which disease was studied in cadiss trial?", "[PAD] what disease is studied in the cadiss process?", "[PAD] which disease was studied in the cadiss trial?", "[PAD] what disease was studied in the cadiss trial?", "[PAD] which disease was studied in the cadiss test?", "[PAD] [PAD] which disease was tested in cadiss trials?", "[PAD] what disease was examined in the cadiss trial?", "[PAD] what disease was studied in the cadiss study?", "[PAD] which disease was studied in the cadiss study?", "[PAD] [PAD] what disease was the cadiss trial studied?", "[PAD] what disease was investigated in the cadiss study?", "[PAD] [PAD] [PAD] what disease was studied in cadiss?", "[PAD] what diseases were studied in the cadiss trial?", "what disease has been studied in the cadiss trial?", "[PAD] which diseases were studied in the cadiss trial?", "[PAD] what diseases were studied in the cadiss exam?", "[PAD] which disease was investigated in the cadiss trial?", "[PAD] what disease was studied in the cadis trial?", "[PAD] what disease was examined in the cadiss study?", "[PAD] [PAD] which disease was studied in cadiss trial?", "[PAD] what disease is studied in the cadiss process?", "[PAD] which disease was studied in the cadiss trial?", "[PAD] what disease was studied in the cadiss trial?", "[PAD] which disease was studied in the cadiss test?", "[PAD] [PAD] which disease was tested in cadiss trials?", "[PAD] what disease was examined in the cadiss trial?", "[PAD] what disease was studied in the cadiss study?", "[PAD] which disease was studied in the cadiss study?", "[PAD] [PAD] what disease was the cadiss trial studied?", "[PAD] what disease was investigated in the cadiss study?", "[PAD] [PAD] [PAD] what disease was studied in cadiss?", "[PAD] what diseases were studied in the cadiss trial?", "what disease has been studied in the cadiss trial?", "[PAD] which diseases were studied in the cadiss trial?", "[PAD] what diseases were studied in the cadiss exam?", "[PAD] which disease was investigated in the cadiss trial?", "[PAD] what disease was studied in the cadis trial?", "[PAD] what disease was examined in the cadiss study?", "[PAD] [PAD] which disease was studied in cadiss trial?", "[PAD] what disease is studied in the cadiss process?", "[PAD] which disease was studied in the cadiss trial?", "[PAD] what disease was studied in the cadiss trial?", "[PAD] which disease was studied in the cadiss test?", "[PAD] [PAD] which disease was tested in cadiss trials?", "[PAD] what disease was examined in the cadiss trial?", "[PAD] what disease was studied in the cadiss study?", "[PAD] which disease was studied in the cadiss study?", "[PAD] [PAD] what disease was the cadiss trial studied?", "[PAD] what disease was investigated in the cadiss study?", "[PAD] [PAD] [PAD] what disease was studied in cadiss?", "[PAD] what diseases were studied in the cadiss trial?", "what disease has been studied in the cadiss trial?", "[PAD] which diseases were studied in the cadiss trial?", "[PAD] what diseases were studied in the cadiss exam?", "[PAD] which disease was investigated in the cadiss trial?", "[PAD] what disease was studied in the cadis trial?", "[PAD] what disease was examined in the cadiss study?", "[PAD] [PAD] which disease was studied in cadiss trial?", "[PAD] what disease is studied in the cadiss process?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "which receptor is modulated with siponimod?", "[PAD] what receptors are modified with siponimod?", "which receptor is modulated by siponimod?", "[PAD] [PAD] which receptor modulates siponymod?", "[PAD] which receptors are regulated by sipomod?", "[PAD] which receptor does siponimod modulate?", "[PAD] what receptors does siponimod modulate?", "which receiver is modulated with siponimod?", "which receptor is modulated by a syndicate?", "[PAD] which receptor is regulated by siponimod?", "which receptors are modulated with siponimod?", "[PAD] which receptor is regulated with siponimod?", "[PAD] which receptor is shaped by siponimod?", "[PAD] which receptor is modified with siponimod?", "[PAD] which receptors are regulated by siponimod?", "which receptors are regulated by siphonimod?", "which receptor is modulated with siponomid?", "[PAD] which receptor is siponimod modulated?", "what receptor is modulated by siponimod?", "what receptor is modulated with siponimod?", "which receiver has been modified by siponimod?", "[PAD] [PAD] which receptor modulates siponimod?", "[PAD] what is the protective efficacy of vaxchora against moderate to severe cholera?", "[PAD] [PAD] [PAD] what is the protective efficacy of the vaccine against moderate to severe cholera?", "what is the preventive efficacy of vaxchora against moderate to severe cholera?", "[PAD] [PAD] [PAD] what is the protective effect of scarecrow against moderate to severe cholera?", "[PAD] [PAD] what is the protective effect of vaxchora against moderate and severe plague?", "[PAD] what is the protective effect of vaxchora on moderate and severe cholera?", "[PAD] [PAD] [PAD] what is the protective effectiveness of waxer against moderate to severe cholera?", "[PAD] what is the protective effect of vaxchora against moderate to severe cholera?", "[PAD] what is the protective effectiveness of vaxchore against moderate to severe cholera?", "[PAD] what is the protective effectiveness of vaxchora against moderate to severe cholera?", "[PAD] [PAD] what is the effectiveness of vaxchora against moderate to severe cholera?", "[PAD] [PAD] what are the protective effects of vaxora against mild to severe cholera?", "[PAD] what is the effectiveness of vaxchora protection against moderate and severe cholera?", "[PAD] [PAD] what is the effectiveness of waxchura protection against moderate to severe cholera?", "[PAD] [PAD] what is the protective efficacy of vaxora against moderate to severe cholera?", "[PAD] [PAD] what is the protective effect of waxchora against moderate to severe cholera?", "what is the effectiveness of vaxchora in protecting against moderate to severe cholera?", "[PAD] what is the effectiveness of vaxchora protection against moderate to severe cholera?", "[PAD] [PAD] what is the protective efficacy of moderate to severe cholera vaxchora?", "[PAD] [PAD] what is the protective efficacy of vaxchor against moderate to severe cholera?", "[PAD] [PAD] [PAD] [PAD] how protective is vaxchora against moderate to severe cholera?", "[PAD] [PAD] what is the protective efficacy of vaxhora against moderate to severe cholera?", "[PAD] [PAD] [PAD] what is the protective effectiveness of vachora against moderate to severe cholera?", "[PAD] what is the effectiveness of vaxchora immunization against moderate to severe cholera?", "[PAD] [PAD] [PAD] what protective effect does wax chora have against moderate to severe cholera?", "[PAD] what is the preventive efficacy of waxcora against moderate to severe cholera?", "[PAD] [PAD] what is the protective effectiveness of vakshora against moderate to severe cholera?", "[PAD] what is the protective effect of vaxchura against moderate to severe cholera?", "[PAD] [PAD] what is the protective efficacy of waxchora against moderate to severe cholera?", "[PAD] what is the function of a viral peplomer?", "[PAD] [PAD] what is the function of a viral pepper spray?", "[PAD] [PAD] [PAD] what is the function of viral oval shell?", "[PAD] what is the function of viral peplomers?", "[PAD] what is the function of the viral peplomer?", "what is the function of a viral peplomero?", "[PAD] [PAD] what is the function of a viral ash meter?", "[PAD] what is the function of the virus peplomer?", "[PAD] what is the role of a viral peptomer?", "[PAD] [PAD] [PAD] what is the function of a viral veil?", "[PAD] what is the role of viral papillomer?", "[PAD] [PAD] what is the function of viral peplomer?", "[PAD] [PAD] [PAD] [PAD] what is the role of viral syndrome?", "[PAD] [PAD] what is the function of virus peplomer?", "[PAD] [PAD] what is the function of a viral fire meter?", "[PAD] [PAD] what is the function of viral plumer?", "[PAD] what is the function of the viral peplometer?", "[PAD] what is the function of the peplomer virus?", "[PAD] what is the function of viral papilloma?", "[PAD] [PAD] what is the function of a virus scanner?", "[PAD] what is the function of a viral plumber?", "[PAD] [PAD] when was vivotif first licenced in europe?", "[PAD] [PAD] [PAD] when was vivotif first licensed in europe?", "[PAD] when did vivotif first get a license in europe?", "[PAD] [PAD] [PAD] when was vivotif first given in europe?", "[PAD] [PAD] [PAD] when did vivotif first graduate in europe?", "[PAD] [PAD] [PAD] when was vivotif first approved in europe?", "[PAD] [PAD] [PAD] when was vivotif first authorized in europe?", "[PAD] [PAD] when did you first receive vivotif in europe?", "when did you first get a vivotif license in europe?", "[PAD] [PAD] [PAD] when was vivotiff first licensed in europe?", "[PAD] [PAD] when was the first vivotif license in europe?", "[PAD] when did vivotif obtain its first license in europe?", "[PAD] [PAD] when was the vivotif first licensed in europe?", "[PAD] [PAD] [PAD] when was vivotef first licensed in europe?", "[PAD] [PAD] what animal is thought to be the host for the coronavirus causing mers?", "[PAD] which animal is thought to be the host for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is believed to be a host for the mers-cov?", "[PAD] which animal is thought to be the host of the mers-induced coronavirus?", "[PAD] which animal is considered to be the host of the coronavirus that causes mers?", "[PAD] what animal is thought to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] which animal is considered to host the coronavirus causing mers?", "[PAD] [PAD] [PAD] [PAD] which animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is considered to be the host for the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is believed to be the host of mers that causes the coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which animal would host the coronavirus causing mers?", "[PAD] [PAD] what animal is thought to be the host of mers that causes coronavirus?", "[PAD] which animal is considered to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] what animal is considered the host for the coronavirus that causes mers?", "[PAD] [PAD] which animal do you think is the host for coronavirus that causes mers?", "[PAD] which animal is considered to be a host to the corona virus that causes mers?", "[PAD] which animal is believed to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] which animal is the owner of the coronavirus-causing mers?", "[PAD] what animal is suspected to be the host of the corona virus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the coronary virus that causes mers?", "[PAD] what animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animals are considered hosts for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host for the mers that causes coronavirus?", "[PAD] what animal is thought to be the host of the corona virus that causes measles?", "[PAD] [PAD] [PAD] [PAD] [PAD] what animal is considered a carrier of the mers coronavirus?", "[PAD] what animal is believed to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] what animal is considered a carrier of the coronavirus that causes mers?", "which animal is considered to be the host for the coronavirus virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is supposed to host the coronavirus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the crown virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is the host of the corona virus that causes mers?", "[PAD] [PAD] [PAD] which animal is thought to be the host for the mers coronavirus?", "[PAD] [PAD] which animal is supposed to be the host for the mers causing coronavirus?", "[PAD] [PAD] what animal is thought to be the host for the coronavirus causing mers?", "[PAD] which animal is thought to be the host for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is believed to be a host for the mers-cov?", "[PAD] which animal is thought to be the host of the mers-induced coronavirus?", "[PAD] which animal is considered to be the host of the coronavirus that causes mers?", "[PAD] what animal is thought to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] which animal is considered to host the coronavirus causing mers?", "[PAD] [PAD] [PAD] [PAD] which animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is considered to be the host for the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is believed to be the host of mers that causes the coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which animal would host the coronavirus causing mers?", "[PAD] [PAD] what animal is thought to be the host of mers that causes coronavirus?", "[PAD] which animal is considered to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] what animal is considered the host for the coronavirus that causes mers?", "[PAD] [PAD] which animal do you think is the host for coronavirus that causes mers?", "[PAD] which animal is considered to be a host to the corona virus that causes mers?", "[PAD] which animal is believed to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] which animal is the owner of the coronavirus-causing mers?", "[PAD] what animal is suspected to be the host of the corona virus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the coronary virus that causes mers?", "[PAD] what animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animals are considered hosts for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host for the mers that causes coronavirus?", "[PAD] what animal is thought to be the host of the corona virus that causes measles?", "[PAD] [PAD] [PAD] [PAD] [PAD] what animal is considered a carrier of the mers coronavirus?", "[PAD] what animal is believed to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] what animal is considered a carrier of the coronavirus that causes mers?", "which animal is considered to be the host for the coronavirus virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is supposed to host the coronavirus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the crown virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is the host of the corona virus that causes mers?", "[PAD] [PAD] [PAD] which animal is thought to be the host for the mers coronavirus?", "[PAD] [PAD] which animal is supposed to be the host for the mers causing coronavirus?", "[PAD] [PAD] what animal is thought to be the host for the coronavirus causing mers?", "[PAD] which animal is thought to be the host for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is believed to be a host for the mers-cov?", "[PAD] which animal is thought to be the host of the mers-induced coronavirus?", "[PAD] which animal is considered to be the host of the coronavirus that causes mers?", "[PAD] what animal is thought to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] which animal is considered to host the coronavirus causing mers?", "[PAD] [PAD] [PAD] [PAD] which animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is considered to be the host for the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is believed to be the host of mers that causes the coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which animal would host the coronavirus causing mers?", "[PAD] [PAD] what animal is thought to be the host of mers that causes coronavirus?", "[PAD] which animal is considered to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] what animal is considered the host for the coronavirus that causes mers?", "[PAD] [PAD] which animal do you think is the host for coronavirus that causes mers?", "[PAD] which animal is considered to be a host to the corona virus that causes mers?", "[PAD] which animal is believed to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] which animal is the owner of the coronavirus-causing mers?", "[PAD] what animal is suspected to be the host of the corona virus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the coronary virus that causes mers?", "[PAD] what animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animals are considered hosts for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host for the mers that causes coronavirus?", "[PAD] what animal is thought to be the host of the corona virus that causes measles?", "[PAD] [PAD] [PAD] [PAD] [PAD] what animal is considered a carrier of the mers coronavirus?", "[PAD] what animal is believed to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] what animal is considered a carrier of the coronavirus that causes mers?", "which animal is considered to be the host for the coronavirus virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is supposed to host the coronavirus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the crown virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is the host of the corona virus that causes mers?", "[PAD] [PAD] [PAD] which animal is thought to be the host for the mers coronavirus?", "[PAD] [PAD] which animal is supposed to be the host for the mers causing coronavirus?", "[PAD] [PAD] what animal is thought to be the host for the coronavirus causing mers?", "[PAD] which animal is thought to be the host for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is believed to be a host for the mers-cov?", "[PAD] which animal is thought to be the host of the mers-induced coronavirus?", "[PAD] which animal is considered to be the host of the coronavirus that causes mers?", "[PAD] what animal is thought to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] which animal is considered to host the coronavirus causing mers?", "[PAD] [PAD] [PAD] [PAD] which animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is considered to be the host for the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is believed to be the host of mers that causes the coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which animal would host the coronavirus causing mers?", "[PAD] [PAD] what animal is thought to be the host of mers that causes coronavirus?", "[PAD] which animal is considered to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] what animal is considered the host for the coronavirus that causes mers?", "[PAD] [PAD] which animal do you think is the host for coronavirus that causes mers?", "[PAD] which animal is considered to be a host to the corona virus that causes mers?", "[PAD] which animal is believed to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] which animal is the owner of the coronavirus-causing mers?", "[PAD] what animal is suspected to be the host of the corona virus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the coronary virus that causes mers?", "[PAD] what animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animals are considered hosts for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host for the mers that causes coronavirus?", "[PAD] what animal is thought to be the host of the corona virus that causes measles?", "[PAD] [PAD] [PAD] [PAD] [PAD] what animal is considered a carrier of the mers coronavirus?", "[PAD] what animal is believed to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] what animal is considered a carrier of the coronavirus that causes mers?", "which animal is considered to be the host for the coronavirus virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is supposed to host the coronavirus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the crown virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is the host of the corona virus that causes mers?", "[PAD] [PAD] [PAD] which animal is thought to be the host for the mers coronavirus?", "[PAD] [PAD] which animal is supposed to be the host for the mers causing coronavirus?", "[PAD] [PAD] what animal is thought to be the host for the coronavirus causing mers?", "[PAD] which animal is thought to be the host for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is believed to be a host for the mers-cov?", "[PAD] which animal is thought to be the host of the mers-induced coronavirus?", "[PAD] which animal is considered to be the host of the coronavirus that causes mers?", "[PAD] what animal is thought to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] which animal is considered to host the coronavirus causing mers?", "[PAD] [PAD] [PAD] [PAD] which animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is considered to be the host for the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is believed to be the host of mers that causes the coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which animal would host the coronavirus causing mers?", "[PAD] [PAD] what animal is thought to be the host of mers that causes coronavirus?", "[PAD] which animal is considered to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] what animal is considered the host for the coronavirus that causes mers?", "[PAD] [PAD] which animal do you think is the host for coronavirus that causes mers?", "[PAD] which animal is considered to be a host to the corona virus that causes mers?", "[PAD] which animal is believed to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] which animal is the owner of the coronavirus-causing mers?", "[PAD] what animal is suspected to be the host of the corona virus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the coronary virus that causes mers?", "[PAD] what animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animals are considered hosts for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host for the mers that causes coronavirus?", "[PAD] what animal is thought to be the host of the corona virus that causes measles?", "[PAD] [PAD] [PAD] [PAD] [PAD] what animal is considered a carrier of the mers coronavirus?", "[PAD] what animal is believed to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] what animal is considered a carrier of the coronavirus that causes mers?", "which animal is considered to be the host for the coronavirus virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is supposed to host the coronavirus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the crown virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is the host of the corona virus that causes mers?", "[PAD] [PAD] [PAD] which animal is thought to be the host for the mers coronavirus?", "[PAD] [PAD] which animal is supposed to be the host for the mers causing coronavirus?", "[PAD] [PAD] what animal is thought to be the host for the coronavirus causing mers?", "[PAD] which animal is thought to be the host for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is believed to be a host for the mers-cov?", "[PAD] which animal is thought to be the host of the mers-induced coronavirus?", "[PAD] which animal is considered to be the host of the coronavirus that causes mers?", "[PAD] what animal is thought to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] which animal is considered to host the coronavirus causing mers?", "[PAD] [PAD] [PAD] [PAD] which animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is considered to be the host for the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is believed to be the host of mers that causes the coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which animal would host the coronavirus causing mers?", "[PAD] [PAD] what animal is thought to be the host of mers that causes coronavirus?", "[PAD] which animal is considered to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] what animal is considered the host for the coronavirus that causes mers?", "[PAD] [PAD] which animal do you think is the host for coronavirus that causes mers?", "[PAD] which animal is considered to be a host to the corona virus that causes mers?", "[PAD] which animal is believed to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] which animal is the owner of the coronavirus-causing mers?", "[PAD] what animal is suspected to be the host of the corona virus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the coronary virus that causes mers?", "[PAD] what animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animals are considered hosts for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host for the mers that causes coronavirus?", "[PAD] what animal is thought to be the host of the corona virus that causes measles?", "[PAD] [PAD] [PAD] [PAD] [PAD] what animal is considered a carrier of the mers coronavirus?", "[PAD] what animal is believed to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] what animal is considered a carrier of the coronavirus that causes mers?", "which animal is considered to be the host for the coronavirus virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is supposed to host the coronavirus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the crown virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is the host of the corona virus that causes mers?", "[PAD] [PAD] [PAD] which animal is thought to be the host for the mers coronavirus?", "[PAD] [PAD] which animal is supposed to be the host for the mers causing coronavirus?", "[PAD] [PAD] what animal is thought to be the host for the coronavirus causing mers?", "[PAD] which animal is thought to be the host for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is believed to be a host for the mers-cov?", "[PAD] which animal is thought to be the host of the mers-induced coronavirus?", "[PAD] which animal is considered to be the host of the coronavirus that causes mers?", "[PAD] what animal is thought to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] which animal is considered to host the coronavirus causing mers?", "[PAD] [PAD] [PAD] [PAD] which animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is considered to be the host for the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is believed to be the host of mers that causes the coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which animal would host the coronavirus causing mers?", "[PAD] [PAD] what animal is thought to be the host of mers that causes coronavirus?", "[PAD] which animal is considered to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] what animal is considered the host for the coronavirus that causes mers?", "[PAD] [PAD] which animal do you think is the host for coronavirus that causes mers?", "[PAD] which animal is considered to be a host to the corona virus that causes mers?", "[PAD] which animal is believed to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] which animal is the owner of the coronavirus-causing mers?", "[PAD] what animal is suspected to be the host of the corona virus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the coronary virus that causes mers?", "[PAD] what animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animals are considered hosts for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host for the mers that causes coronavirus?", "[PAD] what animal is thought to be the host of the corona virus that causes measles?", "[PAD] [PAD] [PAD] [PAD] [PAD] what animal is considered a carrier of the mers coronavirus?", "[PAD] what animal is believed to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] what animal is considered a carrier of the coronavirus that causes mers?", "which animal is considered to be the host for the coronavirus virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is supposed to host the coronavirus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the crown virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is the host of the corona virus that causes mers?", "[PAD] [PAD] [PAD] which animal is thought to be the host for the mers coronavirus?", "[PAD] [PAD] which animal is supposed to be the host for the mers causing coronavirus?", "[PAD] [PAD] what animal is thought to be the host for the coronavirus causing mers?", "[PAD] which animal is thought to be the host for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is believed to be a host for the mers-cov?", "[PAD] which animal is thought to be the host of the mers-induced coronavirus?", "[PAD] which animal is considered to be the host of the coronavirus that causes mers?", "[PAD] what animal is thought to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] which animal is considered to host the coronavirus causing mers?", "[PAD] [PAD] [PAD] [PAD] which animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is considered to be the host for the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animal is thought to host the coronavirus that causes mers?", "[PAD] which animal is believed to be the host of mers that causes the coronavirus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which animal would host the coronavirus causing mers?", "[PAD] [PAD] what animal is thought to be the host of mers that causes coronavirus?", "[PAD] which animal is considered to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] what animal is considered the host for the coronavirus that causes mers?", "[PAD] [PAD] which animal do you think is the host for coronavirus that causes mers?", "[PAD] which animal is considered to be a host to the corona virus that causes mers?", "[PAD] which animal is believed to be the host of the mers-causing coronavirus?", "[PAD] [PAD] [PAD] [PAD] which animal is the owner of the coronavirus-causing mers?", "[PAD] what animal is suspected to be the host of the corona virus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the coronary virus that causes mers?", "[PAD] what animal is thought to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] [PAD] what animals are considered hosts for the coronavirus that causes mers?", "[PAD] which animal is thought to be the host for the mers that causes coronavirus?", "[PAD] what animal is thought to be the host of the corona virus that causes measles?", "[PAD] [PAD] [PAD] [PAD] [PAD] what animal is considered a carrier of the mers coronavirus?", "[PAD] what animal is believed to be the host of the coronavirus that causes mers?", "[PAD] [PAD] [PAD] what animal is considered a carrier of the coronavirus that causes mers?", "which animal is considered to be the host for the coronavirus virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is supposed to host the coronavirus that causes mers?", "[PAD] [PAD] which animal is thought to be the host of the crown virus that causes mers?", "[PAD] [PAD] [PAD] [PAD] which animal is the host of the corona virus that causes mers?", "[PAD] [PAD] [PAD] which animal is thought to be the host for the mers coronavirus?", "[PAD] [PAD] which animal is supposed to be the host for the mers causing coronavirus?", "[PAD] how many proteins have been queried for protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins were queried for protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how much protein is required for protein partners from the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins were asked for protein partners in the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins were surveyed for protein partners with the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how much protein has been consulted for protein partners via the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins were requested for protein partners on the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how much protein was asked for protein partners from the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how much protein has been consulted for protein partners using the drosophila protein interaction map (dpim)?", "how many proteins have been queried as chaperones in the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how much protein was tested for protein partners using the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins were queried for protein partners using the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins have been asked for protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins have been asked about protein partners using the drosophila protein interaction card (dpim)?", "[PAD] [PAD] [PAD] how many proteins were queried for the drosophila protein interaction map (dpim) protein partners?", "[PAD] [PAD] how many proteins have been asked for protein partners on the drosophila protein interaction map (dpim)?", "[PAD] how many proteins were interrogated for protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins were consulted for protein partners using the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins were required for protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins have been asked about protein partners from the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] [PAD] how much protein was required for protein partners by four drosophila protein interactions (dpim)?", "[PAD] [PAD] [PAD] how many proteins were tested for protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins did the drosophila protein interaction map (dpim) query for protein partners?", "[PAD] [PAD] how many proteins have been requested for protein partners with the drosophila protein interaction card (dpim)?", "[PAD] how much protein is interrogated by a drosophila protein interaction map (dpim) for protein partners?", "[PAD] how many proteins were queried for their protein partners in the drosophila protein interaction map (dpim)?", "[PAD] how much protein have been queried by protein partners using the drosophila protein interaction card (dpim)?", "[PAD] [PAD] [PAD] how much protein was queried for the protein partner drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how much protein is required for protein partners with the drosophila protein interaction map (dpim)?", "[PAD] how many proteins have been asked for a protein partner by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins were asked for protein partners from the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins have been questioned for protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins were queried by protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins were searched for protein partners using the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins were queried for protein partners with the drosophila protein interaction map (dpim)?", "[PAD] how many proteins have been queried for protein partners using the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] [PAD] how many proteins were asked for protein partners and drosophila (dpim) protein interaction map?", "[PAD] [PAD] [PAD] how many proteins are searched for protein partners by the drosophila protein interaction map (dpim).", "how many proteins were interrogated for their protein partners by the drosophila protein interaction map (dpim)?", "how many proteins were asked for the presence of protein partners using the drosophila protein interaction map (dpim)?", "[PAD] [PAD] [PAD] how many proteins have been requested for protein partners through drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins have been asked about protein partners by the drosophila protein interaction map (dpim)?", "[PAD] [PAD] how many proteins have been asked for protein partners through the drosophila protein interaction site (dpim)?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic to which disease?", "[PAD] [PAD] [PAD] central vein sign is characteristic of which disease?", "for which disease is the sign of the central vein characteristic?", "[PAD] [PAD] [PAD] [PAD] what disease is the central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous sign?", "[PAD] [PAD] what disease is characterized by a central venous mark?", "what diseases are characterized by the sign of the central vein?", "which disease is characterized by a feature of the central vein?", "the sign of the central vein is characteristic of which disease?", "the sign of the central vein is characteristic of what disease?", "[PAD] [PAD] which disease is characterized by the central vein sign?", "which disease is characterized by the sign of the central vein?", "[PAD] [PAD] what disease is characteristic of the central venous sign?", "[PAD] [PAD] [PAD] central vein sign is characteristic of what disease?", "what disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] central vein sign is characteristic in which disease?", "[PAD] [PAD] which disease is characterized by a central venous marker?", "[PAD] [PAD] the central venous sign is characteristic of which disease?", "what disease is characterized by the signal from the central vein?", "in which disease is the sign of the central vein characteristic?", "[PAD] [PAD] what are the hallmarks of central venous disease?", "[PAD] [PAD] [PAD] a major vein sign typical of which disease?", "[PAD] [PAD] [PAD] what disease is characterized by central vein sign?", "[PAD] [PAD] which disease is characterized by a central venous signal?", "[PAD] [PAD] [PAD] central vein sign is characteristic of any disease?", "[PAD] [PAD] central vein sign is a feature of what disease?", "what is the disease of the sign of central venice?", "[PAD] [PAD] the central vein sign is characteristic of which disease?", "[PAD] [PAD] which disease is the central vein sign characteristic of?", "[PAD] [PAD] [PAD] what diseases are characterized by central venous signs?", "[PAD] [PAD] [PAD] which disease is characterized by a central vein?", "[PAD] [PAD] what is the characteristic feature of the central vein?", "[PAD] [PAD] [PAD] central venous signs are characteristic of which disease?", "[PAD] [PAD] is the central vein sign characteristic of which disease?", "what is the characteristic symptom of central venous disease?", "for which disease is the central sign of the vein characteristic?", "is the sign of the central vein characteristic of which disease?", "[PAD] central venous symptom is typical for what disease?", "[PAD] which disease is a characteristic feature of the central vein?", "which disease is characterized by a sign of the central vein?", "[PAD] [PAD] [PAD] what is the characteristic of the central vector?", "[PAD] [PAD] [PAD] central ven sign is characteristic of which disease?", "[PAD] [PAD] what kind of disease does central vein sign have?", "[PAD] [PAD] [PAD] central vein scar is characteristic of which disease?", "[PAD] [PAD] [PAD] what is the central venous sign characteristic of?", "[PAD] [PAD] [PAD] central vein sign is characteristic for which disease?", "[PAD] which type of cells protect haematopoietic stem and progenitor cells (hspcs) from ultraviolet-light-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] what type of cells protect hematopoietic stem and stem cells (hspcs) from ultraviolet light-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] what cell types protect hematopoietic stem and progenitor cells (hspcs) from dna damage caused by ultraviolet rays in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] what type of cells protect hematopoietic stem cells and progenitor cells (hspcs) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what types of cells protect hematopoietic stem cells (hspcs) from dna damage caused by ultraviolet light from aquatic vertebrates?", "[PAD] [PAD] in aquatic vertebrates, which cell type protects hematopoietic stem and progenitor cells (hspc) from dna damage caused by ultraviolet light?", "[PAD] [PAD] [PAD] what types of cells protect hematopoietic stem cells and progenitors (hspc) from damage caused by ultraviolet light in vertebrate water?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what type of cells protect stem cells and progenitor cells (hspcs) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] what type of cells protect hematopoietic stem and progenitor cells (hspcs) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] what type of cells protect hematopoietic stem and progenitor cells (hspcs) from ultraviolet-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which cell type protects hematopoietic stem and progenitor cells (hspc) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] what cell type protects hematopoietic stem and progenitor cells (hspcs) from dna damage caused by ultraviolet light in aquatic vertebrates?", "[PAD] [PAD] what type of cells protect hematopoietic stem and progenitor cells (hspc) from dna damage in aquatic vertebrates caused by ultraviolet light?", "[PAD] [PAD] what type of cells protect hematopoietic stem and progenitor cells (hspcs) from dna damage induced by ultraviolet light in aquatic vertebrates?", "[PAD] [PAD] what type of cells protect hematopoietic stem and progenitor cells (hspcs) from ultraviolet light-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] what types of cells protect aquatic vertebrate hematopoietic stem and progenitor cells (hspc) from dna damage caused by ultraviolet light?", "[PAD] what type of cells protect hematopoietic stem and progenitor cells (hspcs) from dna damage caused by ultraviolet-light in aquatic vertebrates?", "[PAD] [PAD] what types of cells protect hematopoietic stem and progenitor cells (hspcs) from dna damage in aquatic vertebrates caused by ultraviolet light?", "[PAD] [PAD] [PAD] what cell type protects hematopoietic stem and progenitor cells (hspcs) from ultraviolet light-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] what types of cells protect hematopoietic stem and precursor cells (hspcs) from dna damage caused by ultraviolet light in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cell type protects hematopoietic stem and progenitor cells (hspcs) from uv light-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cell type protects hematopoietic stem cells and progenitor cells (hspcs) from uv-induced dna damage in aquatic vertebrates?", "what types of cells protect hematopoietic stem cells and progenitor cells (hspcs) from dna damage induced by ultraviolet light in aquatic vertebrae?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what type of cells protect stem cells and progenitors (hspcs) from dna damage induced by ultraviolet light in aquatic vertebrates?", "[PAD] what types of cells protect hematopoietic stem and progenitor cells (hspcs) from ultraviolet-light-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] what types of cells protect hematopoietic stem and progenitor cells (hspcs) from ultraviolet-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] what type of cells protect hematopoietic stem cells and stem cells (hspcs) from dna damage caused by ultraviolet light in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cell types protect haematopoietic stem cells and progenitor cells (hspc) from uv damage to dna in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] what type of cells protect haematopoietic stem and genital cells (hspcs) from ultraviolet-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] what types of cells protect hematopoietic stem cells and progenitor cells (hspcs) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] what types of cells protect hematopoietic stem and progenitor cells (hspcs) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] what types of cells protect hematopoietic stem and stem cells (hspc) from uv damage to aquatic vertebrates caused by ultraviolet light?", "[PAD] [PAD] what type of cells protect hematopoietic stem and progenitor cells (hspcs) from dna damage caused by ultraviolet light in aquatic vertebrates?", "[PAD] [PAD] what types of cells protect hematopoietic stem cells and progenitors (hspcs) from dna damage due to ultraviolet light in aquatic vertebrates?", "what type of cells protect hematopoietic and progenitor stem cells (hspcs) from damage caused by ultraviolet light-induced dna in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which cell type protects hematopoietic stem cells (hspcs) from dna damage caused by ultraviolet radiation in aquatic vertebrates?", "[PAD] [PAD] what type of cell protects hematopoietic stem and progenitor cells (hspcs) from ultraviolet radiation-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] what cell types protect hematopoietic stem and progenitor cells (hspcs) from ultraviolet light-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] what type of cells protect hematopoietic stem cells and progenitors (hspc) from ultraviolet-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which cell type protects hematopoietic stem and progenitor cells (hspcs) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cell types protect hematopoietic stem and progenitor cells (hspcs) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cell type protects hematopoietic stem and progenitor cells (hspc) from ultraviolet light dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cell types protect hematopoietic stem cells (hspcs) from dna damage caused by ultraviolet light in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] what type of cells protect hematopoietic stem and progenitor cells (hspc) from uv-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] [PAD] [PAD] what type of cells protect the stem and cervical cells (hspcs) from dna damage caused by light-colored light in aquatic invertebrates?", "[PAD] [PAD] what type of cells protect hematopoietic stem and progenitor cells (hspc) from dna damage caused by ultraviolet light in aquatic vertebrates?", "what types of cells protect hematopoietic progenitor cells and progenitor cells (hspcs) from ultraviolet-induced dna damage in aquatic vertebrates?", "[PAD] [PAD] [PAD] which cell type protects hematopoietic stem and progenitor cells (hspcs) from dna damage caused by ultraviolet light in aquatic vertebrates?", "[PAD] [PAD] [PAD] what types of cells protect hematopoietic stem and progenitor cells (hspcs) from damage to dna in ultraviolet light in aquatic animals?", "[PAD] what type of cells protect haematopoietic stem cells and progenitor cells (hspcs) from dna damage caused by ultraviolet light in aquatic vertebrates?", "[PAD] what type of cells protect hematopoietic stem and progenitor cells (hspcs) from ultraviolet-light-induced dna damage in water vertebrates?", "what is the target of the drug remdesivir?", "[PAD] [PAD] what is the goal of remedisivir?", "what is the purpose of the drug remdesivir?", "[PAD] [PAD] what is the target of remedisivir?", "[PAD] [PAD] what is the purpose of remdesivir?", "[PAD] [PAD] [PAD] what is remdezivir aimed at?", "what is the goal of the drug remdesivir?", "[PAD] [PAD] what is the goal of remdesivir?", "[PAD] [PAD] what is the target of remdesivir?", "[PAD] [PAD] what is the target drug remdesivir?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is remdesivir?", "what is the target of the drug remedisivir?", "what is the purpose of the drug remedisivir?", "[PAD] [PAD] what is the purpose of drug remission?", "[PAD] what is the target of remdesivir drug?", "what is the goal of the remdesivir drug?", "[PAD] [PAD] what is the purpose of remedisivir?", "[PAD] what is the target of remdesivir medication?", "[PAD] [PAD] what is the purpose of remedsivir?", "what is the purpose of the remdesivir drug?", "[PAD] cushing's disease is associated with a tumor in what part of the body?", "[PAD] cushing's disease is associated with a tumor in which part of the body?", "[PAD] [PAD] [PAD] [PAD] what part of the body is cushing's disease associated with?", "which cushing's disease is associated with which part of the body's tumor?", "[PAD] [PAD] in which part of the body is cushing's disease associated with tumors?", "[PAD] in which parts of the body is cushing's disease associated with a tumor?", "[PAD] is cushing's disease associated with a tumor in any part of the body?", "[PAD] [PAD] [PAD] [PAD] where in the body is cushing's disease associated with tumors?", "[PAD] in what part of the body is cushing's disease associated with the tumor?", "[PAD] is cushing's disease associated with a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is associated with cancer in which part of the body?", "[PAD] cushing's disease is related to a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is related to tumors in which part of the body?", "[PAD] [PAD] in which part of the body is cushing's disease associated with cancer?", "[PAD] [PAD] cushing's disease is associated with tumors in which parts of the body?", "[PAD] [PAD] which part of the body is cushing's disease associated with a tumor?", "[PAD] [PAD] [PAD] [PAD] where is cushing's disease associated with tumors in the body?", "[PAD] in which part of the body is cushing's disease associated with the tumor?", "[PAD] cushing's disease is associated with a tumor on which part of the body?", "[PAD] [PAD] cushing's disease is associated with tumors in which part of the body?", "[PAD] in which part of the body is cushing's disease associated with a tumor?", "[PAD] cushing's disease is related to a tumor in what part of the body?", "[PAD] [PAD] [PAD] where in the body is cushing's disease associated with a tumor?", "[PAD] [PAD] cushing's disease is associated with swelling in what part of the body?", "[PAD] [PAD] [PAD] in what parts of the body does cushing's disease involve tumors?", "[PAD] cushing's disease is associated with a tumor in what part of the body?", "[PAD] cushing's disease is associated with a tumor in which part of the body?", "[PAD] [PAD] [PAD] [PAD] what part of the body is cushing's disease associated with?", "which cushing's disease is associated with which part of the body's tumor?", "[PAD] [PAD] in which part of the body is cushing's disease associated with tumors?", "[PAD] in which parts of the body is cushing's disease associated with a tumor?", "[PAD] is cushing's disease associated with a tumor in any part of the body?", "[PAD] [PAD] [PAD] [PAD] where in the body is cushing's disease associated with tumors?", "[PAD] in what part of the body is cushing's disease associated with the tumor?", "[PAD] is cushing's disease associated with a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is associated with cancer in which part of the body?", "[PAD] cushing's disease is related to a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is related to tumors in which part of the body?", "[PAD] [PAD] in which part of the body is cushing's disease associated with cancer?", "[PAD] [PAD] cushing's disease is associated with tumors in which parts of the body?", "[PAD] [PAD] which part of the body is cushing's disease associated with a tumor?", "[PAD] [PAD] [PAD] [PAD] where is cushing's disease associated with tumors in the body?", "[PAD] in which part of the body is cushing's disease associated with the tumor?", "[PAD] cushing's disease is associated with a tumor on which part of the body?", "[PAD] [PAD] cushing's disease is associated with tumors in which part of the body?", "[PAD] in which part of the body is cushing's disease associated with a tumor?", "[PAD] cushing's disease is related to a tumor in what part of the body?", "[PAD] [PAD] [PAD] where in the body is cushing's disease associated with a tumor?", "[PAD] [PAD] cushing's disease is associated with swelling in what part of the body?", "[PAD] [PAD] [PAD] in what parts of the body does cushing's disease involve tumors?", "[PAD] cushing's disease is associated with a tumor in what part of the body?", "[PAD] cushing's disease is associated with a tumor in which part of the body?", "[PAD] [PAD] [PAD] [PAD] what part of the body is cushing's disease associated with?", "which cushing's disease is associated with which part of the body's tumor?", "[PAD] [PAD] in which part of the body is cushing's disease associated with tumors?", "[PAD] in which parts of the body is cushing's disease associated with a tumor?", "[PAD] is cushing's disease associated with a tumor in any part of the body?", "[PAD] [PAD] [PAD] [PAD] where in the body is cushing's disease associated with tumors?", "[PAD] in what part of the body is cushing's disease associated with the tumor?", "[PAD] is cushing's disease associated with a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is associated with cancer in which part of the body?", "[PAD] cushing's disease is related to a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is related to tumors in which part of the body?", "[PAD] [PAD] in which part of the body is cushing's disease associated with cancer?", "[PAD] [PAD] cushing's disease is associated with tumors in which parts of the body?", "[PAD] [PAD] which part of the body is cushing's disease associated with a tumor?", "[PAD] [PAD] [PAD] [PAD] where is cushing's disease associated with tumors in the body?", "[PAD] in which part of the body is cushing's disease associated with the tumor?", "[PAD] cushing's disease is associated with a tumor on which part of the body?", "[PAD] [PAD] cushing's disease is associated with tumors in which part of the body?", "[PAD] in which part of the body is cushing's disease associated with a tumor?", "[PAD] cushing's disease is related to a tumor in what part of the body?", "[PAD] [PAD] [PAD] where in the body is cushing's disease associated with a tumor?", "[PAD] [PAD] cushing's disease is associated with swelling in what part of the body?", "[PAD] [PAD] [PAD] in what parts of the body does cushing's disease involve tumors?", "[PAD] cushing's disease is associated with a tumor in what part of the body?", "[PAD] cushing's disease is associated with a tumor in which part of the body?", "[PAD] [PAD] [PAD] [PAD] what part of the body is cushing's disease associated with?", "which cushing's disease is associated with which part of the body's tumor?", "[PAD] [PAD] in which part of the body is cushing's disease associated with tumors?", "[PAD] in which parts of the body is cushing's disease associated with a tumor?", "[PAD] is cushing's disease associated with a tumor in any part of the body?", "[PAD] [PAD] [PAD] [PAD] where in the body is cushing's disease associated with tumors?", "[PAD] in what part of the body is cushing's disease associated with the tumor?", "[PAD] is cushing's disease associated with a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is associated with cancer in which part of the body?", "[PAD] cushing's disease is related to a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is related to tumors in which part of the body?", "[PAD] [PAD] in which part of the body is cushing's disease associated with cancer?", "[PAD] [PAD] cushing's disease is associated with tumors in which parts of the body?", "[PAD] [PAD] which part of the body is cushing's disease associated with a tumor?", "[PAD] [PAD] [PAD] [PAD] where is cushing's disease associated with tumors in the body?", "[PAD] in which part of the body is cushing's disease associated with the tumor?", "[PAD] cushing's disease is associated with a tumor on which part of the body?", "[PAD] [PAD] cushing's disease is associated with tumors in which part of the body?", "[PAD] in which part of the body is cushing's disease associated with a tumor?", "[PAD] cushing's disease is related to a tumor in what part of the body?", "[PAD] [PAD] [PAD] where in the body is cushing's disease associated with a tumor?", "[PAD] [PAD] cushing's disease is associated with swelling in what part of the body?", "[PAD] [PAD] [PAD] in what parts of the body does cushing's disease involve tumors?", "[PAD] cushing's disease is associated with a tumor in what part of the body?", "[PAD] cushing's disease is associated with a tumor in which part of the body?", "[PAD] [PAD] [PAD] [PAD] what part of the body is cushing's disease associated with?", "which cushing's disease is associated with which part of the body's tumor?", "[PAD] [PAD] in which part of the body is cushing's disease associated with tumors?", "[PAD] in which parts of the body is cushing's disease associated with a tumor?", "[PAD] is cushing's disease associated with a tumor in any part of the body?", "[PAD] [PAD] [PAD] [PAD] where in the body is cushing's disease associated with tumors?", "[PAD] in what part of the body is cushing's disease associated with the tumor?", "[PAD] is cushing's disease associated with a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is associated with cancer in which part of the body?", "[PAD] cushing's disease is related to a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is related to tumors in which part of the body?", "[PAD] [PAD] in which part of the body is cushing's disease associated with cancer?", "[PAD] [PAD] cushing's disease is associated with tumors in which parts of the body?", "[PAD] [PAD] which part of the body is cushing's disease associated with a tumor?", "[PAD] [PAD] [PAD] [PAD] where is cushing's disease associated with tumors in the body?", "[PAD] in which part of the body is cushing's disease associated with the tumor?", "[PAD] cushing's disease is associated with a tumor on which part of the body?", "[PAD] [PAD] cushing's disease is associated with tumors in which part of the body?", "[PAD] in which part of the body is cushing's disease associated with a tumor?", "[PAD] cushing's disease is related to a tumor in what part of the body?", "[PAD] [PAD] [PAD] where in the body is cushing's disease associated with a tumor?", "[PAD] [PAD] cushing's disease is associated with swelling in what part of the body?", "[PAD] [PAD] [PAD] in what parts of the body does cushing's disease involve tumors?", "[PAD] cushing's disease is associated with a tumor in what part of the body?", "[PAD] cushing's disease is associated with a tumor in which part of the body?", "[PAD] [PAD] [PAD] [PAD] what part of the body is cushing's disease associated with?", "which cushing's disease is associated with which part of the body's tumor?", "[PAD] [PAD] in which part of the body is cushing's disease associated with tumors?", "[PAD] in which parts of the body is cushing's disease associated with a tumor?", "[PAD] is cushing's disease associated with a tumor in any part of the body?", "[PAD] [PAD] [PAD] [PAD] where in the body is cushing's disease associated with tumors?", "[PAD] in what part of the body is cushing's disease associated with the tumor?", "[PAD] is cushing's disease associated with a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is associated with cancer in which part of the body?", "[PAD] cushing's disease is related to a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is related to tumors in which part of the body?", "[PAD] [PAD] in which part of the body is cushing's disease associated with cancer?", "[PAD] [PAD] cushing's disease is associated with tumors in which parts of the body?", "[PAD] [PAD] which part of the body is cushing's disease associated with a tumor?", "[PAD] [PAD] [PAD] [PAD] where is cushing's disease associated with tumors in the body?", "[PAD] in which part of the body is cushing's disease associated with the tumor?", "[PAD] cushing's disease is associated with a tumor on which part of the body?", "[PAD] [PAD] cushing's disease is associated with tumors in which part of the body?", "[PAD] in which part of the body is cushing's disease associated with a tumor?", "[PAD] cushing's disease is related to a tumor in what part of the body?", "[PAD] [PAD] [PAD] where in the body is cushing's disease associated with a tumor?", "[PAD] [PAD] cushing's disease is associated with swelling in what part of the body?", "[PAD] [PAD] [PAD] in what parts of the body does cushing's disease involve tumors?", "[PAD] cushing's disease is associated with a tumor in what part of the body?", "[PAD] cushing's disease is associated with a tumor in which part of the body?", "[PAD] [PAD] [PAD] [PAD] what part of the body is cushing's disease associated with?", "which cushing's disease is associated with which part of the body's tumor?", "[PAD] [PAD] in which part of the body is cushing's disease associated with tumors?", "[PAD] in which parts of the body is cushing's disease associated with a tumor?", "[PAD] is cushing's disease associated with a tumor in any part of the body?", "[PAD] [PAD] [PAD] [PAD] where in the body is cushing's disease associated with tumors?", "[PAD] in what part of the body is cushing's disease associated with the tumor?", "[PAD] is cushing's disease associated with a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is associated with cancer in which part of the body?", "[PAD] cushing's disease is related to a tumor in which part of the body?", "[PAD] [PAD] cushing's disease is related to tumors in which part of the body?", "[PAD] [PAD] in which part of the body is cushing's disease associated with cancer?", "[PAD] [PAD] cushing's disease is associated with tumors in which parts of the body?", "[PAD] [PAD] which part of the body is cushing's disease associated with a tumor?", "[PAD] [PAD] [PAD] [PAD] where is cushing's disease associated with tumors in the body?", "[PAD] in which part of the body is cushing's disease associated with the tumor?", "[PAD] cushing's disease is associated with a tumor on which part of the body?", "[PAD] [PAD] cushing's disease is associated with tumors in which part of the body?", "[PAD] in which part of the body is cushing's disease associated with a tumor?", "[PAD] cushing's disease is related to a tumor in what part of the body?", "[PAD] [PAD] [PAD] where in the body is cushing's disease associated with a tumor?", "[PAD] [PAD] cushing's disease is associated with swelling in what part of the body?", "[PAD] [PAD] [PAD] in what parts of the body does cushing's disease involve tumors?", "what classes of drugs does retapamulin belong to?", "to which classes of medicine does retapamulin belong?", "what class of drugs does retapamulin belong to?", "[PAD] retapamulin belongs to which group of drugs?", "[PAD] [PAD] what class of drug is retapamulin?", "[PAD] to what classes of drugs belongs retapamulin?", "what kind of drugs does retapamulin belong to?", "[PAD] what class of drugs does retapalene belong to?", "to which group of drugs does retapamulin belong?", "what group of medicines does retapamulin belong to?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is retapamulin?", "[PAD] what types of drugs belong to retapamulin?", "[PAD] what drug classes does retapamulin belong to?", "[PAD] [PAD] what are the classes of retapamulin?", "what categories of drugs does retapamulin belong to?", "[PAD] [PAD] what grade does retapamulin belong to?", "what types of medications does retampoline belong to?", "[PAD] what drug categories does retapamulin belong to?", "[PAD] which drug classes does retapamulin belong to?", "what class of medicine does retapamulin belong to?", "which classes of medicines does retapamulin belong to?", "what classes of medicines does retapamulin belong to?", "what class of drugs does ratapamulin belong to?", "[PAD] [PAD] which classes of drugs is retapamulin?", "[PAD] to which drug classes does retapamulin belong?", "what class of medicines does retapamulin belong to?", "to which class of drugs does retapamulin belong?", "to which groups of drugs does retapamulin belong?", "[PAD] [PAD] what kind of medicine is retapamulin?", "[PAD] which classes of drugs belong to retapamulin?", "retapamulin is classified as what type of medication?", "[PAD] to which classes of drugs belongs retapamulin?", "[PAD] retapamulin belongs to which class of drugs?", "what classes of drugs does retapamulin fall into?", "[PAD] what classes of drugs retapamulin belongs to?", "what classes of drugs does retapamulin belong to?", "to which classes of medicine does retapamulin belong?", "what class of drugs does retapamulin belong to?", "[PAD] retapamulin belongs to which group of drugs?", "[PAD] [PAD] what class of drug is retapamulin?", "[PAD] to what classes of drugs belongs retapamulin?", "what kind of drugs does retapamulin belong to?", "[PAD] what class of drugs does retapalene belong to?", "to which group of drugs does retapamulin belong?", "what group of medicines does retapamulin belong to?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is retapamulin?", "[PAD] what types of drugs belong to retapamulin?", "[PAD] what drug classes does retapamulin belong to?", "[PAD] [PAD] what are the classes of retapamulin?", "what categories of drugs does retapamulin belong to?", "[PAD] [PAD] what grade does retapamulin belong to?", "what types of medications does retampoline belong to?", "[PAD] what drug categories does retapamulin belong to?", "[PAD] which drug classes does retapamulin belong to?", "what class of medicine does retapamulin belong to?", "which classes of medicines does retapamulin belong to?", "what classes of medicines does retapamulin belong to?", "what class of drugs does ratapamulin belong to?", "[PAD] [PAD] which classes of drugs is retapamulin?", "[PAD] to which drug classes does retapamulin belong?", "what class of medicines does retapamulin belong to?", "to which class of drugs does retapamulin belong?", "to which groups of drugs does retapamulin belong?", "[PAD] [PAD] what kind of medicine is retapamulin?", "[PAD] which classes of drugs belong to retapamulin?", "retapamulin is classified as what type of medication?", "[PAD] to which classes of drugs belongs retapamulin?", "[PAD] retapamulin belongs to which class of drugs?", "what classes of drugs does retapamulin fall into?", "[PAD] what classes of drugs retapamulin belongs to?", "what classes of drugs does retapamulin belong to?", "to which classes of medicine does retapamulin belong?", "what class of drugs does retapamulin belong to?", "[PAD] retapamulin belongs to which group of drugs?", "[PAD] [PAD] what class of drug is retapamulin?", "[PAD] to what classes of drugs belongs retapamulin?", "what kind of drugs does retapamulin belong to?", "[PAD] what class of drugs does retapalene belong to?", "to which group of drugs does retapamulin belong?", "what group of medicines does retapamulin belong to?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is retapamulin?", "[PAD] what types of drugs belong to retapamulin?", "[PAD] what drug classes does retapamulin belong to?", "[PAD] [PAD] what are the classes of retapamulin?", "what categories of drugs does retapamulin belong to?", "[PAD] [PAD] what grade does retapamulin belong to?", "what types of medications does retampoline belong to?", "[PAD] what drug categories does retapamulin belong to?", "[PAD] which drug classes does retapamulin belong to?", "what class of medicine does retapamulin belong to?", "which classes of medicines does retapamulin belong to?", "what classes of medicines does retapamulin belong to?", "what class of drugs does ratapamulin belong to?", "[PAD] [PAD] which classes of drugs is retapamulin?", "[PAD] to which drug classes does retapamulin belong?", "what class of medicines does retapamulin belong to?", "to which class of drugs does retapamulin belong?", "to which groups of drugs does retapamulin belong?", "[PAD] [PAD] what kind of medicine is retapamulin?", "[PAD] which classes of drugs belong to retapamulin?", "retapamulin is classified as what type of medication?", "[PAD] to which classes of drugs belongs retapamulin?", "[PAD] retapamulin belongs to which class of drugs?", "what classes of drugs does retapamulin fall into?", "[PAD] what classes of drugs retapamulin belongs to?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] [PAD] [PAD] rachmilewitz index is used for which diseases?", "[PAD] [PAD] [PAD] for which diseases is rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz index used?", "[PAD] [PAD] for which diseases is the rachmilewitz indicator used?", "[PAD] [PAD] for what diseases is the rachmilewitz index used?", "[PAD] [PAD] what diseases is the rachmilewitz index used for?", "[PAD] [PAD] for which diseases is the rakhmilevich index used?", "[PAD] [PAD] [PAD] what diseases is the rahmilewitz index used for?", "[PAD] [PAD] what diseases is the rachmirwitz index used for?", "[PAD] [PAD] the rachmilewitz index is used for which diseases?", "[PAD] in what diseases is the rakhmilevits index used?", "[PAD] [PAD] [PAD] [PAD] rachmilewitz index used for what diseases?", "what is the rachmilevitch index used for which diseases?", "[PAD] [PAD] in what diseases is the rachmilewitz index used?", "[PAD] [PAD] [PAD] rachmilewitz index is used for what diseases?", "[PAD] [PAD] what disease is the rachmilewitz index used for?", "[PAD] [PAD] [PAD] [PAD] which diseases are used rachmilewitz index?", "[PAD] what diseases is the rachmilewitz index used to treat?", "[PAD] [PAD] for which diseases is the rahmilevitz index used?", "[PAD] [PAD] for what diseases is the rakhmilewitz index used?", "[PAD] for which diseases is the rachmilevitz index used?", "[PAD] [PAD] what diseases does the rachmilewitz index apply to?", "[PAD] [PAD] in which diseases is the rachmilewitz index used?", "[PAD] for which diseases is the rakhmilevica index used?", "[PAD] [PAD] [PAD] for what diseases is rachmilewitz index used?", "[PAD] [PAD] [PAD] rakhmilevich index is used for which diseases?", "[PAD] which molecule is targeted by camrelizumab?", "[PAD] [PAD] what molecule does camrelizumab target?", "[PAD] [PAD] which molecule is camrelizumab targeting?", "[PAD] [PAD] which molecule does camrelizumab target?", "[PAD] [PAD] what molecules does camrelizumab target?", "which molecule is the target of camrelizumab?", "[PAD] [PAD] which molecule is camrelizumab targeted?", "[PAD] [PAD] [PAD] what is camrelizumab targeted?", "[PAD] [PAD] [PAD] [PAD] what is camrelizumab?", "what molecule is the target of camrelizumab?", "[PAD] which molecule is camrelizumab targeted to?", "[PAD] which molecule is targeted by camralizumab?", "[PAD] which molecule is concentrated on camrelizumab?", "[PAD] [PAD] which molecule does camrelizumab cover?", "[PAD] which molecules are targeted by camrelizumab?", "[PAD] what molecules are targeted by camrelizumab?", "[PAD] which molecule is camrelizumab aimed at?", "[PAD] [PAD] [PAD] camrelizumab targets which molecule?", "[PAD] which part of the tnfr2 gene is genetically associated with systemic lupus erythematosus?", "[PAD] what part of the tnfr2 gene is genetically associated with systemic lupus erythematosus?", "[PAD] which part of the tnfr2 gene is genetically linked to systemic lupus erythematosus?", "[PAD] which part of the tnfr2 gene is genetically related to systemic lupus erythematosus?", "[PAD] what part of the tnfr2 gene is genetically linked to systemic lupus erythematosus?", "[PAD] what part of the tnfr2 gene is genetically related to systemic lupus erythematosus?", "[PAD] [PAD] which part of tnfr2 genes is genetically associated with systemic lupus erythematosus?", "[PAD] [PAD] [PAD] what part of the tnfr2 gene is genetically linked to systemic arrhythmia lupus?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what part of the tnfr2 gene is genetically linked to red wolves?", "what part of the tnfr2 gene is genetically linked to the systemic lupus erythematosus?", "what is the effect of satb1 knock-out in mice?", "[PAD] [PAD] what is the effect of satb1 knockout in mice?", "what is the effect of knock-out satb1 on rats?", "[PAD] [PAD] what is the effect of satb1 knockdown in mice?", "[PAD] [PAD] what is the effect of satb1 knockout on mice?", "what is the effect of satb1 knock-out on mice?", "[PAD] [PAD] what is the effect of knockout satb1 in mice?", "[PAD] what is the effect of a satb1 knockout in mice?", "[PAD] [PAD] what is the effect of satb1 elimination on mice?", "[PAD] [PAD] what are the effects of satb1 knockout in mice?", "[PAD] what is the effect of the satb1 knockout in mice?", "[PAD] what is the effect of turning off satb1 on mice?", "what was the effect of satb1 knock-out on rats?", "what are the effects of satb1 knock-out in mice?", "[PAD] what is the effect of satb1 rash in mice?", "[PAD] what is the effect of knocking out satb1 on mice?", "[PAD] [PAD] what is the effect of satb1 knockout in rats?", "[PAD] [PAD] what are the effects of satb1 exclusion on mice?", "[PAD] what are the effects of knocking out satb1 in mice?", "[PAD] [PAD] what is the knockout effect of satb1 on mice?", "[PAD] [PAD] what is the knockout effect of satb1 in mice?", "[PAD] what is the effect of satb1 secretion in mice?", "[PAD] what is the effect of knocking out satb1 in mice?", "[PAD] [PAD] [PAD] what are the effects of satb1 in mice?", "[PAD] [PAD] how large is a lncrnas?", "[PAD] [PAD] [PAD] how big are lncrnas?", "[PAD] [PAD] how big is a lncarns?", "[PAD] what is the size of lncrnas?", "[PAD] what is the size of lncrna?", "[PAD] [PAD] how big is an lncrna?", "[PAD] [PAD] how much is an lncrna?", "[PAD] [PAD] [PAD] how big is lncrna?", "[PAD] [PAD] how big is the lncrna?", "[PAD] [PAD] how big is a lncrna?", "[PAD] [PAD] how big are an lncrnas?", "[PAD] [PAD] what size is an lncrnas?", "[PAD] [PAD] how big is a lncrnas?", "what is the size of an lncrnas?", "[PAD] [PAD] [PAD] how big is lncrnas?", "what is the size of an lncrna?", "[PAD] [PAD] [PAD] what size is lncrna?", "[PAD] [PAD] how big is an lncrnas?", "[PAD] [PAD] [PAD] how big is an incrna?", "what is telangiectasia?", "[PAD] [PAD] [PAD] what is teleinjection?", "[PAD] how is zp-pth delivered to patients?", "[PAD] how is zp-pth distributed to patients?", "[PAD] how is zp-pth transmitted to patients?", "[PAD] how is zp-pth given to patients?", "[PAD] how is zp-pth administered to patients?", "[PAD] how is zp-pth sent to patients?", "how is zp-pth delivered to the patient?", "name a selective nk3r agonist.", "name the selective nk3r agonist.", "name the selected nk3r agonist.", "named a selective nk3r agonist.", "[PAD] [PAD] named selective nk3r agonists.", "specify a selective nk3r agonist.", "appoint a selective nk3r agonist.", "[PAD] name a selective nk3r fighter.", "appoint a nk3r selective agonist.", "name a specific nk3r agonist.", "name an optional nk3r agonist.", "list a selective nk3r agonist.", "[PAD] name the selected nk3r agonists.", "[PAD] name nk3r selective agonist.", "replace a selective nk3r agonist.", "[PAD] specify the selected nk3r character.", "[PAD] name the selected nk3r protagonist.", "name a selected nk3r agonist.", "name a select nk3r agonist.", "[PAD] [PAD] in which cells does tlr7 escape x-chromosome inactivation?", "[PAD] [PAD] [PAD] in which cells does tlr7 x chromosome inactivation escape?", "[PAD] [PAD] in which tlr7 cells does it escape x chromosome inactivation?", "in which cells does tlr7 escape from inactivation of the x chromosome?", "[PAD] [PAD] in which cells does tlr7 avoid deactivation of the x chromosome?", "[PAD] [PAD] in which cells does tlr7 avoid x-chromosome inactivation?", "[PAD] [PAD] [PAD] in which cells does tlr7 escape x chromosome inactivation?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cells does tlr7 escape x chromosome activation?", "[PAD] in which cells does tlr7 escape inactivation of the x chromosome?", "[PAD] [PAD] in which cells does tlr7 prevent x-chromosome inactivation?", "[PAD] [PAD] [PAD] in which cells does tlr7 escape the inactive x-chromosome?", "[PAD] [PAD] [PAD] in which tlr7 cells does x chromosome inactivation escape?", "in which cells does tlr7 escape the inactivation of the x chromosome?", "[PAD] [PAD] [PAD] in which tlr7 cells escape x-chromosome inactivation?", "[PAD] [PAD] [PAD] [PAD] [PAD] in which cells does tlr7 escape x-activation?", "[PAD] [PAD] [PAD] in which cells does tlr7 escape x chromosome inactivity?", "[PAD] [PAD] [PAD] in which tlr7 cells does x chromosome inactivate escape?", "[PAD] [PAD] [PAD] in which cells does tlr7 release x chromosome inactivation?", "[PAD] in which tlr7 cells it avoids x-chromosome inactivation?", "[PAD] [PAD] in which tlr7 cells do they escape x chromosome inactivation?", "[PAD] [PAD] [PAD] in which cells does tlr7 avoid x chromosome inactivation?", "[PAD] [PAD] in which cells does tlr7 avoid the activation of the x chromosome?", "[PAD] [PAD] [PAD] in which cell does tlr7 escape x chromosome inactivation?", "[PAD] [PAD] [PAD] [PAD] tlr7 prevents x chromosome inactivation in which cells?", "[PAD] [PAD] in which cell does tlr7 escape x-chromosome inactivation?", "in which cells does tlr7 escape inactivation of x-chromosomes?", "[PAD] [PAD] how many copies of tp53 does the elephant genome contain?", "how many copies of tp53 does the elephant's genome contain?", "[PAD] how many copies of tp53 are there in the elephant genome?", "[PAD] [PAD] [PAD] how many copies of the elephant genome have tp53?", "[PAD] [PAD] [PAD] how many tp53s does the elephant genome contain?", "[PAD] [PAD] how many copies of tp53 does the ivory genome contain?", "[PAD] [PAD] [PAD] how many copies of the elephant genome tp53 have?", "[PAD] [PAD] how many copies of tp53 are there in elephant genome?", "[PAD] how many copies of tp53 are contained in the elephant genome?", "[PAD] [PAD] how many copies of tp53 are in the elephant genome?", "[PAD] [PAD] how many versions of tp53 does the elephant genome have?", "[PAD] [PAD] how many copies of the tp53 gene do you have?", "[PAD] [PAD] how many copies of the elephant genome does tp53 have?", "[PAD] [PAD] how many copies of tp53 does the elephant genome contain?", "how many copies of tp53 does the elephant's genome contain?", "[PAD] how many copies of tp53 are there in the elephant genome?", "[PAD] [PAD] [PAD] how many copies of the elephant genome have tp53?", "[PAD] [PAD] [PAD] how many tp53s does the elephant genome contain?", "[PAD] [PAD] how many copies of tp53 does the ivory genome contain?", "[PAD] [PAD] [PAD] how many copies of the elephant genome tp53 have?", "[PAD] [PAD] how many copies of tp53 are there in elephant genome?", "[PAD] how many copies of tp53 are contained in the elephant genome?", "[PAD] [PAD] how many copies of tp53 are in the elephant genome?", "[PAD] [PAD] how many versions of tp53 does the elephant genome have?", "[PAD] [PAD] how many copies of the tp53 gene do you have?", "[PAD] [PAD] how many copies of the elephant genome does tp53 have?"], "title": ["5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2f0afcfbd6abf43b000028", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5e2902e48b3851296d000006", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5c74285c7c78d694710000a3", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e2b2c85fbd6abf43b000007", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5e3da25848dab47f26000004", "5d31b847b3a6380763000002", "5d31b847b3a6380763000002", "5d31b847b3a6380763000002", "5d31b847b3a6380763000002", "5d31b847b3a6380763000002", "5d31b847b3a6380763000002", "5d31b847b3a6380763000002", "5d31b847b3a6380763000002", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e4940f46d0a277941000004", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e31cceafbd6abf43b000052", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5e3c6c9eb5b409ea53000022", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5d387aa8a1e159510500000f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5e31cbd4fbd6abf43b00004f", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5d35f1267bc3fee31f000004", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e460f823f54159529000006", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e4604d83f54159529000003", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e48a916d14c9f295d00000f", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e76452fc6a8763d23000015", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e5bafa01af46fc130000002", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e763bd4c6a8763d2300000f", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e2f4a8bfbd6abf43b00002a", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e35dc26158f994d3a000006", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e4601293f54159529000002", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e36cf8eb5b409ea53000007", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e6de3f21af46fc130000022", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e669e401af46fc13000001a", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e5e50751af46fc13000000b", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e47546d3f54159529000019", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5e4b540b6d0a27794100001c", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d386ed6a1e1595105000004", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5d36b8a37bc3fee31f000009", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e6e8f92c6a8763d23000004", "5e3c686fb5b409ea53000020", "5e3c686fb5b409ea53000020", "5e7f64d6835f4e477700001f", "5e7f64d6835f4e477700001f", "5e7f64d6835f4e477700001f", "5e7f64d6835f4e477700001f", "5e7f64d6835f4e477700001f", "5e7f64d6835f4e477700001f", "5e7f64d6835f4e477700001f", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5e5438c3b761aafe09000003", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d38767ca1e159510500000b", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018", "5d388535a1e1595105000018"], "new_id": ["0_0", "0_1", "0_2", "0_3", "0_4", "0_5", "0_6", "0_7", "0_8", "0_9", "0_10", "0_11", "0_12", "0_13", "0_14", "0_15", "0_16", "0_17", "0_18", "0_19", "0_20", "1_0", "1_1", "1_2", "1_3", "1_4", "1_5", "1_6", "1_7", "1_8", "1_9", "1_10", "1_11", "1_12", "1_13", "1_14", "1_15", "1_16", "1_17", "1_18", "1_19", "1_20", "2_0", "2_1", "2_2", "2_3", "2_4", "2_5", "2_6", "2_7", "2_8", "2_9", "2_10", "2_11", "2_12", "2_13", "2_14", "2_15", "2_16", "2_17", "2_18", "2_19", "2_20", "3_0", "3_1", "3_2", "3_3", "3_4", "3_5", "3_6", "3_7", "3_8", "3_9", "3_10", "3_11", "3_12", "3_13", "3_14", "3_15", "3_16", "3_17", "3_18", "3_19", "3_20", "4_0", "4_1", "4_2", "4_3", "4_4", "4_5", "4_6", "4_7", "5_0", "5_1", "5_2", "5_3", "5_4", "5_5", "5_6", "5_7", "6_0", "6_1", "6_2", "6_3", "6_4", "6_5", "6_6", "6_7", "7_0", "7_1", "7_2", "7_3", "7_4", "7_5", "7_6", "7_7", "8_0", "8_1", "8_2", "8_3", "8_4", "8_5", "8_6", "8_7", "9_0", "9_1", "9_2", "9_3", "9_4", "9_5", "9_6", "9_7", "10_0", "10_1", "10_2", "10_3", "10_4", "10_5", "10_6", "10_7", "11_0", "11_1", "11_2", "11_3", "11_4", "11_5", "11_6", "11_7", "12_0", "12_1", "12_2", "12_3", "12_4", "12_5", "12_6", "12_7", "13_0", "13_1", "13_2", "13_3", "13_4", "13_5", "13_6", "13_7", "13_8", "13_9", "13_10", "13_11", "13_12", "13_13", "13_14", "13_15", "13_16", "13_17", "13_18", "13_19", "13_20", "13_21", "13_22", "13_23", "13_24", "13_25", "13_26", "13_27", "13_28", "13_29", "13_30", "13_31", "13_32", "13_33", "13_34", "13_35", "14_0", "14_1", "14_2", "14_3", "14_4", "14_5", "14_6", "14_7", "14_8", "14_9", "14_10", "14_11", "14_12", "14_13", "14_14", "14_15", "14_16", "14_17", "14_18", "14_19", "14_20", "14_21", "14_22", "14_23", "14_24", "14_25", "14_26", "14_27", "14_28", "14_29", "14_30", "14_31", "14_32", "14_33", "14_34", "14_35", "15_0", "15_1", "15_2", "15_3", "15_4", "15_5", "15_6", "15_7", "15_8", "15_9", "15_10", "15_11", "15_12", "15_13", "15_14", "15_15", "15_16", "15_17", "15_18", "15_19", "15_20", "15_21", "15_22", "15_23", "15_24", "15_25", "15_26", "15_27", "15_28", "15_29", "15_30", "15_31", "15_32", "15_33", "15_34", "15_35", "16_0", "16_1", "16_2", "16_3", "16_4", "16_5", "16_6", "16_7", "16_8", "16_9", "16_10", "16_11", "16_12", "16_13", "16_14", "16_15", "16_16", "16_17", "16_18", "16_19", "16_20", "16_21", "16_22", "16_23", "16_24", "16_25", "16_26", "16_27", "16_28", "16_29", "16_30", "16_31", "16_32", "16_33", "16_34", "16_35", "17_0", "17_1", "17_2", "17_3", "17_4", "17_5", "17_6", "17_7", "17_8", "17_9", "17_10", "17_11", "17_12", "17_13", "17_14", "17_15", "17_16", "17_17", "17_18", "17_19", "17_20", "17_21", "17_22", "17_23", "17_24", "17_25", "17_26", "17_27", "17_28", "17_29", "17_30", "17_31", "17_32", "17_33", "17_34", "17_35", "18_0", "18_1", "18_2", "18_3", "18_4", "18_5", "18_6", "18_7", "18_8", "18_9", "18_10", "18_11", "18_12", "18_13", "18_14", "18_15", "18_16", "18_17", "18_18", "18_19", "18_20", "18_21", "18_22", "18_23", "18_24", "18_25", "18_26", "18_27", "18_28", "18_29", "18_30", "18_31", "18_32", "18_33", "18_34", "18_35", "19_0", "19_1", "19_2", "19_3", "19_4", "19_5", "19_6", "19_7", "19_8", "19_9", "19_10", "19_11", "19_12", "19_13", "19_14", "19_15", "19_16", "19_17", "19_18", "19_19", "19_20", "19_21", "19_22", "19_23", "19_24", "19_25", "19_26", "19_27", "19_28", "19_29", "19_30", "19_31", "19_32", "19_33", "19_34", "19_35", "20_0", "20_1", "20_2", "20_3", "20_4", "20_5", "20_6", "20_7", "20_8", "20_9", "20_10", "20_11", "20_12", "20_13", "20_14", "20_15", "20_16", "20_17", "20_18", "20_19", "20_20", "20_21", "20_22", "20_23", "20_24", "20_25", "20_26", "20_27", "20_28", "20_29", "20_30", "20_31", "20_32", "20_33", "20_34", "20_35", "21_0", "21_1", "21_2", "21_3", "21_4", "21_5", "21_6", "21_7", "21_8", "21_9", "21_10", "21_11", "21_12", "21_13", "21_14", "21_15", "21_16", "21_17", "21_18", "21_19", "21_20", "21_21", "21_22", "21_23", "21_24", "21_25", "21_26", "21_27", "21_28", "21_29", "21_30", "21_31", "21_32", "21_33", "21_34", "21_35", "22_0", "22_1", "22_2", "22_3", "22_4", "22_5", "22_6", "22_7", "22_8", "22_9", "22_10", "22_11", "22_12", "22_13", "22_14", "22_15", "22_16", "22_17", "22_18", "22_19", "22_20", "22_21", "22_22", "22_23", "23_0", "23_1", "23_2", "23_3", "23_4", "23_5", "23_6", "23_7", "23_8", "23_9", "23_10", "23_11", "23_12", "23_13", "23_14", "23_15", "23_16", "23_17", "23_18", "23_19", "23_20", "23_21", "23_22", "23_23", "24_0", "24_1", "24_2", "24_3", "24_4", "24_5", "24_6", "24_7", "24_8", "24_9", "24_10", "24_11", "24_12", "24_13", "24_14", "24_15", "24_16", "24_17", "24_18", "24_19", "24_20", "24_21", "24_22", "24_23", "25_0", "25_1", "25_2", "25_3", "25_4", "25_5", "25_6", "25_7", "25_8", "25_9", "25_10", "25_11", "25_12", "25_13", "25_14", "25_15", "25_16", "25_17", "25_18", "25_19", "25_20", "25_21", "25_22", "25_23", "26_0", "26_1", "26_2", "26_3", "26_4", "26_5", "26_6", "26_7", "26_8", "26_9", "26_10", "26_11", "26_12", "26_13", "26_14", "27_0", "27_1", "27_2", "27_3", "27_4", "27_5", "27_6", "27_7", "27_8", "27_9", "27_10", "27_11", "27_12", "27_13", "27_14", "28_0", "28_1", "28_2", "28_3", "28_4", "28_5", "28_6", "28_7", "28_8", "28_9", "28_10", "28_11", "28_12", "28_13", "28_14", "29_0", "29_1", "29_2", "29_3", "29_4", "29_5", "29_6", "29_7", "30_0", "30_1", "30_2", "30_3", "30_4", "30_5", "30_6", "30_7", "30_8", "30_9", "30_10", "30_11", "30_12", "30_13", "30_14", "30_15", "30_16", "30_17", "30_18", "30_19", "30_20", "30_21", "30_22", "30_23", "30_24", "30_25", "30_26", "30_27", "30_28", "30_29", "30_30", "30_31", "30_32", "30_33", "30_34", "30_35", "30_36", "30_37", "30_38", "31_0", "31_1", "31_2", "31_3", "31_4", "31_5", "31_6", "31_7", "31_8", "31_9", "31_10", "31_11", "31_12", "31_13", "31_14", "31_15", "31_16", "31_17", "31_18", "31_19", "31_20", "31_21", "31_22", "31_23", "31_24", "31_25", "31_26", "31_27", "31_28", "31_29", "31_30", "31_31", "31_32", "31_33", "31_34", "31_35", "31_36", "31_37", "31_38", "32_0", "32_1", "32_2", "32_3", "32_4", "32_5", "32_6", "32_7", "32_8", "32_9", "32_10", "32_11", "32_12", "32_13", "32_14", "32_15", "32_16", "32_17", "32_18", "32_19", "32_20", "32_21", "32_22", "32_23", "32_24", "32_25", "32_26", "32_27", "32_28", "32_29", "32_30", "32_31", "32_32", "32_33", "32_34", "32_35", "32_36", "32_37", "32_38", "33_0", "33_1", "33_2", "33_3", "33_4", "33_5", "33_6", "33_7", "33_8", "33_9", "33_10", "33_11", "33_12", "33_13", "33_14", "33_15", "33_16", "33_17", "33_18", "33_19", "33_20", "33_21", "33_22", "33_23", "33_24", "33_25", "33_26", "33_27", "33_28", "33_29", "33_30", "33_31", "33_32", "33_33", "33_34", "33_35", "33_36", "33_37", "33_38", "34_0", "34_1", "34_2", "34_3", "34_4", "34_5", "34_6", "34_7", "34_8", "34_9", "34_10", "34_11", "34_12", "34_13", "34_14", "34_15", "34_16", "34_17", "34_18", "34_19", "34_20", "34_21", "34_22", "34_23", "34_24", "34_25", "34_26", "34_27", "34_28", "34_29", "34_30", "34_31", "34_32", "34_33", "34_34", "34_35", "34_36", "34_37", "34_38", "35_0", "35_1", "35_2", "35_3", "35_4", "35_5", "35_6", "35_7", "35_8", "35_9", "35_10", "35_11", "35_12", "35_13", "35_14", "35_15", "35_16", "35_17", "35_18", "35_19", "35_20", "35_21", "35_22", "35_23", "35_24", "35_25", "35_26", "35_27", "35_28", "35_29", "35_30", "35_31", "35_32", "35_33", "35_34", "35_35", "35_36", "35_37", "35_38", "36_0", "36_1", "36_2", "36_3", "36_4", "36_5", "36_6", "36_7", "36_8", "36_9", "36_10", "36_11", "36_12", "36_13", "36_14", "36_15", "36_16", "36_17", "37_0", "37_1", "37_2", "37_3", "37_4", "37_5", "37_6", "37_7", "37_8", "37_9", "37_10", "37_11", "37_12", "37_13", "37_14", "37_15", "37_16", "37_17", "37_18", "37_19", "37_20", "37_21", "37_22", "37_23", "37_24", "37_25", "38_0", "38_1", "38_2", "38_3", "38_4", "38_5", "38_6", "38_7", "38_8", "38_9", "38_10", "38_11", "38_12", "38_13", "38_14", "38_15", "38_16", "38_17", "38_18", "38_19", "38_20", "38_21", "38_22", "38_23", "38_24", "38_25", "39_0", "39_1", "39_2", "39_3", "39_4", "39_5", "39_6", "39_7", "39_8", "39_9", "39_10", "39_11", "39_12", "39_13", "39_14", "39_15", "39_16", "39_17", "39_18", "39_19", "39_20", "39_21", "39_22", "39_23", "39_24", "39_25", "40_0", "40_1", "40_2", "40_3", "40_4", "40_5", "40_6", "40_7", "40_8", "40_9", "40_10", "40_11", "40_12", "40_13", "40_14", "40_15", "40_16", "40_17", "40_18", "40_19", "40_20", "40_21", "40_22", "40_23", "40_24", "40_25", "41_0", "41_1", "41_2", "41_3", "41_4", "41_5", "41_6", "41_7", "41_8", "41_9", "41_10", "41_11", "41_12", "41_13", "41_14", "41_15", "41_16", "41_17", "41_18", "41_19", "41_20", "41_21", "41_22", "41_23", "41_24", "41_25", "42_0", "42_1", "42_2", "42_3", "42_4", "42_5", "42_6", "42_7", "42_8", "42_9", "42_10", "42_11", "42_12", "42_13", "42_14", "42_15", "42_16", "42_17", "42_18", "42_19", "42_20", "42_21", "42_22", "42_23", "42_24", "42_25", "43_0", "43_1", "43_2", "43_3", "43_4", "43_5", "43_6", "43_7", "43_8", "43_9", "43_10", "43_11", "43_12", "43_13", "43_14", "43_15", "43_16", "43_17", "43_18", "43_19", "43_20", "43_21", "43_22", "43_23", "43_24", "44_0", "44_1", "44_2", "44_3", "44_4", "44_5", "44_6", "44_7", "44_8", "44_9", "44_10", "44_11", "44_12", "44_13", "44_14", "44_15", "44_16", "44_17", "44_18", "44_19", "44_20", "44_21", "44_22", "44_23", "44_24", "45_0", "45_1", "45_2", "45_3", "45_4", "45_5", "45_6", "45_7", "45_8", "45_9", "45_10", "45_11", "45_12", "45_13", "46_0", "46_1", "46_2", "46_3", "46_4", "46_5", "46_6", "46_7", "46_8", "46_9", "46_10", "46_11", "46_12", "46_13", "47_0", "47_1", "47_2", "47_3", "47_4", "47_5", "47_6", "47_7", "47_8", "47_9", "47_10", "47_11", "47_12", "47_13", "48_0", "48_1", "48_2", "48_3", "48_4", "48_5", "48_6", "48_7", "48_8", "48_9", "48_10", "48_11", "48_12", "48_13", "49_0", "49_1", "49_2", "49_3", "49_4", "49_5", "49_6", "49_7", "49_8", "49_9", "49_10", "49_11", "49_12", "49_13", "50_0", "50_1", "50_2", "50_3", "50_4", "50_5", "50_6", "50_7", "50_8", "50_9", "50_10", "50_11", "50_12", "50_13", "51_0", "51_1", "51_2", "51_3", "51_4", "51_5", "51_6", "51_7", "51_8", "51_9", "51_10", "51_11", "51_12", "51_13", "52_0", "52_1", "52_2", "52_3", "52_4", "52_5", "52_6", "52_7", "52_8", "52_9", "52_10", "52_11", "52_12", "52_13", "53_0", "53_1", "53_2", "53_3", "53_4", "53_5", "53_6", "53_7", "53_8", "53_9", "53_10", "53_11", "53_12", "53_13", "54_0", "54_1", "54_2", "54_3", "54_4", "54_5", "54_6", "54_7", "54_8", "54_9", "54_10", "54_11", "54_12", "54_13", "55_0", "55_1", "55_2", "55_3", "55_4", "55_5", "55_6", "55_7", "55_8", "55_9", "55_10", "55_11", "55_12", "55_13", "56_0", "56_1", "56_2", "56_3", "56_4", "56_5", "56_6", "56_7", "56_8", "56_9", "56_10", "57_0", "57_1", "57_2", "57_3", "57_4", "57_5", "57_6", "57_7", "57_8", "57_9", "57_10", "57_11", "57_12", "57_13", "58_0", "58_1", "58_2", "58_3", "58_4", "58_5", "58_6", "58_7", "58_8", "58_9", "58_10", "58_11", "58_12", "58_13", "59_0", "59_1", "59_2", "59_3", "59_4", "59_5", "59_6", "59_7", "59_8", "59_9", "59_10", "59_11", "59_12", "59_13", "60_0", "60_1", "60_2", "60_3", "60_4", "60_5", "60_6", "60_7", "60_8", "60_9", "60_10", "60_11", "60_12", "60_13", "61_0", "61_1", "61_2", "61_3", "61_4", "61_5", "61_6", "61_7", "61_8", "61_9", "61_10", "61_11", "61_12", "61_13", "62_0", "62_1", "62_2", "62_3", "62_4", "62_5", "62_6", "62_7", "62_8", "62_9", "62_10", "62_11", "62_12", "62_13", "63_0", "63_1", "63_2", "63_3", "63_4", "63_5", "63_6", "63_7", "63_8", "63_9", "63_10", "63_11", "63_12", "63_13", "64_0", "64_1", "64_2", "64_3", "64_4", "64_5", "64_6", "64_7", "64_8", "64_9", "64_10", "64_11", "64_12", "64_13", "65_0", "65_1", "65_2", "65_3", "65_4", "65_5", "65_6", "65_7", "65_8", "65_9", "65_10", "65_11", "65_12", "65_13", "66_0", "66_1", "66_2", "66_3", "66_4", "66_5", "66_6", "66_7", "66_8", "66_9", "66_10", "66_11", "66_12", "66_13", "67_0", "67_1", "67_2", "67_3", "67_4", "67_5", "67_6", "67_7", "67_8", "67_9", "67_10", "67_11", "67_12", "67_13", "68_0", "68_1", "68_2", "68_3", "68_4", "68_5", "68_6", "68_7", "68_8", "68_9", "68_10", "68_11", "68_12", "68_13", "69_0", "69_1", "69_2", "69_3", "69_4", "69_5", "69_6", "69_7", "69_8", "69_9", "69_10", "69_11", "69_12", "69_13", "70_0", "70_1", "70_2", "70_3", "70_4", "70_5", "70_6", "70_7", "70_8", "70_9", "70_10", "70_11", "70_12", "70_13", "71_0", "71_1", "71_2", "71_3", "71_4", "71_5", "71_6", "71_7", "71_8", "71_9", "71_10", "71_11", "71_12", "71_13", "72_0", "72_1", "72_2", "72_3", "72_4", "72_5", "72_6", "72_7", "72_8", "72_9", "72_10", "72_11", "72_12", "72_13", "72_14", "72_15", "72_16", "72_17", "72_18", "73_0", "73_1", "73_2", "73_3", "73_4", "73_5", "73_6", "73_7", "73_8", "73_9", "73_10", "73_11", "73_12", "73_13", "73_14", "73_15", "73_16", "73_17", "73_18", "74_0", "74_1", "74_2", "74_3", "74_4", "74_5", "74_6", "74_7", "74_8", "74_9", "74_10", "74_11", "74_12", "74_13", "74_14", "74_15", "74_16", "74_17", "74_18", "75_0", "75_1", "75_2", "75_3", "75_4", "75_5", "75_6", "75_7", "75_8", "75_9", "75_10", "75_11", "75_12", "75_13", "75_14", "75_15", "75_16", "75_17", "75_18", "76_0", "76_1", "76_2", "76_3", "76_4", "76_5", "76_6", "76_7", "76_8", "76_9", "76_10", "76_11", "76_12", "76_13", "76_14", "76_15", "76_16", "76_17", "76_18", "77_0", "77_1", "77_2", "77_3", "77_4", "77_5", "77_6", "77_7", "77_8", "77_9", "77_10", "77_11", "77_12", "77_13", "77_14", "77_15", "77_16", "77_17", "77_18", "77_19", "77_20", "77_21", "78_0", "78_1", "78_2", "78_3", "78_4", "78_5", "78_6", "78_7", "78_8", "78_9", "78_10", "78_11", "78_12", "78_13", "78_14", "78_15", "78_16", "78_17", "78_18", "78_19", "78_20", "78_21", "79_0", "79_1", "79_2", "79_3", "79_4", "79_5", "79_6", "79_7", "79_8", "79_9", "79_10", "79_11", "79_12", "79_13", "79_14", "79_15", "79_16", "79_17", "79_18", "79_19", "79_20", "79_21", "80_0", "80_1", "80_2", "80_3", "80_4", "80_5", "80_6", "80_7", "80_8", "80_9", "80_10", "80_11", "80_12", "80_13", "80_14", "80_15", "80_16", "80_17", "80_18", "80_19", "80_20", "80_21", "81_0", "81_1", "81_2", "81_3", "81_4", "81_5", "81_6", "81_7", "81_8", "81_9", "81_10", "81_11", "81_12", "81_13", "81_14", "81_15", "81_16", "81_17", "81_18", "81_19", "81_20", "81_21", "82_0", "82_1", "82_2", "82_3", "82_4", "82_5", "82_6", "82_7", "82_8", "82_9", "82_10", "82_11", "82_12", "82_13", "82_14", "82_15", "82_16", "82_17", "82_18", "82_19", "82_20", "82_21", "83_0", "83_1", "83_2", "83_3", "83_4", "83_5", "83_6", "83_7", "83_8", "83_9", "83_10", "83_11", "83_12", "83_13", "83_14", "83_15", "83_16", "83_17", "83_18", "83_19", "83_20", "83_21", "84_0", "84_1", "84_2", "84_3", "84_4", "84_5", "84_6", "84_7", "84_8", "84_9", "84_10", "84_11", "84_12", "84_13", "84_14", "84_15", "84_16", "84_17", "84_18", "84_19", "84_20", "84_21", "85_0", "85_1", "85_2", "85_3", "85_4", "85_5", "85_6", "85_7", "85_8", "85_9", "85_10", "85_11", "85_12", "85_13", "85_14", "85_15", "85_16", "85_17", "85_18", "85_19", "85_20", "85_21", "86_0", "86_1", "86_2", "86_3", "86_4", "86_5", "86_6", "86_7", "86_8", "86_9", "86_10", "86_11", "86_12", "86_13", "86_14", "86_15", "86_16", "86_17", "86_18", "86_19", "86_20", "86_21", "87_0", "87_1", "87_2", "87_3", "87_4", "87_5", "87_6", "87_7", "87_8", "87_9", "87_10", "87_11", "87_12", "87_13", "87_14", "87_15", "87_16", "87_17", "87_18", "87_19", "87_20", "87_21", "88_0", "88_1", "88_2", "88_3", "88_4", "88_5", "88_6", "88_7", "88_8", "88_9", "88_10", "88_11", "88_12", "88_13", "88_14", "88_15", "88_16", "88_17", "88_18", "88_19", "88_20", "88_21", "89_0", "89_1", "89_2", "89_3", "89_4", "89_5", "89_6", "89_7", "89_8", "89_9", "89_10", "89_11", "89_12", "89_13", "89_14", "89_15", "89_16", "89_17", "89_18", "89_19", "89_20", "89_21", "90_0", "90_1", "90_2", "90_3", "90_4", "90_5", "90_6", "90_7", "90_8", "90_9", "90_10", "90_11", "90_12", "90_13", "90_14", "90_15", "90_16", "90_17", "90_18", "90_19", "90_20", "90_21", "90_22", "90_23", "90_24", "90_25", "90_26", "90_27", "90_28", "91_0", "91_1", "91_2", "91_3", "91_4", "91_5", "91_6", "91_7", "91_8", "91_9", "91_10", "91_11", "91_12", "91_13", "91_14", "91_15", "91_16", "91_17", "91_18", "91_19", "91_20", "92_0", "92_1", "92_2", "92_3", "92_4", "92_5", "92_6", "92_7", "92_8", "92_9", "92_10", "92_11", "92_12", "92_13", "93_0", "93_1", "93_2", "93_3", "93_4", "93_5", "93_6", "93_7", "93_8", "93_9", "93_10", "93_11", "93_12", "93_13", "93_14", "93_15", "93_16", "93_17", "93_18", "93_19", "93_20", "93_21", "93_22", "93_23", "93_24", "93_25", "93_26", "93_27", "93_28", "93_29", "93_30", "93_31", "93_32", "93_33", "93_34", "94_0", "94_1", "94_2", "94_3", "94_4", "94_5", "94_6", "94_7", "94_8", "94_9", "94_10", "94_11", "94_12", "94_13", "94_14", "94_15", "94_16", "94_17", "94_18", "94_19", "94_20", "94_21", "94_22", "94_23", "94_24", "94_25", "94_26", "94_27", "94_28", "94_29", "94_30", "94_31", "94_32", "94_33", "94_34", "95_0", "95_1", "95_2", "95_3", "95_4", "95_5", "95_6", "95_7", "95_8", "95_9", "95_10", "95_11", "95_12", "95_13", "95_14", "95_15", "95_16", "95_17", "95_18", "95_19", "95_20", "95_21", "95_22", "95_23", "95_24", "95_25", "95_26", "95_27", "95_28", "95_29", "95_30", "95_31", "95_32", "95_33", "95_34", "96_0", "96_1", "96_2", "96_3", "96_4", "96_5", "96_6", "96_7", "96_8", "96_9", "96_10", "96_11", "96_12", "96_13", "96_14", "96_15", "96_16", "96_17", "96_18", "96_19", "96_20", "96_21", "96_22", "96_23", "96_24", "96_25", "96_26", "96_27", "96_28", "96_29", "96_30", "96_31", "96_32", "96_33", "96_34", "97_0", "97_1", "97_2", "97_3", "97_4", "97_5", "97_6", "97_7", "97_8", "97_9", "97_10", "97_11", "97_12", "97_13", "97_14", "97_15", "97_16", "97_17", "97_18", "97_19", "97_20", "97_21", "97_22", "97_23", "97_24", "97_25", "97_26", "97_27", "97_28", "97_29", "97_30", "97_31", "97_32", "97_33", "97_34", "98_0", "98_1", "98_2", "98_3", "98_4", "98_5", "98_6", "98_7", "98_8", "98_9", "98_10", "98_11", "98_12", "98_13", "98_14", "98_15", "98_16", "98_17", "98_18", "98_19", "98_20", "98_21", "98_22", "98_23", "98_24", "98_25", "98_26", "98_27", "98_28", "98_29", "98_30", "98_31", "98_32", "98_33", "98_34", "99_0", "99_1", "99_2", "99_3", "99_4", "99_5", "99_6", "99_7", "99_8", "99_9", "99_10", "99_11", "99_12", "99_13", "99_14", "99_15", "99_16", "99_17", "99_18", "99_19", "99_20", "99_21", "99_22", "99_23", "99_24", "99_25", "99_26", "99_27", "99_28", "99_29", "99_30", "99_31", "99_32", "99_33", "99_34", "100_0", "100_1", "100_2", "100_3", "100_4", "100_5", "100_6", "100_7", "100_8", "100_9", "100_10", "100_11", "100_12", "100_13", "100_14", "100_15", "100_16", "100_17", "100_18", "100_19", "100_20", "100_21", "100_22", "100_23", "100_24", "100_25", "100_26", "100_27", "100_28", "100_29", "100_30", "100_31", "100_32", "100_33", "100_34", "101_0", "101_1", "101_2", "101_3", "101_4", "101_5", "101_6", "101_7", "101_8", "101_9", "101_10", "101_11", "101_12", "101_13", "101_14", "101_15", "101_16", "101_17", "101_18", "101_19", "101_20", "101_21", "101_22", "101_23", "101_24", "101_25", "101_26", "101_27", "101_28", "101_29", "101_30", "101_31", "101_32", "101_33", "101_34", "101_35", "101_36", "101_37", "101_38", "101_39", "101_40", "101_41", "101_42", "102_0", "102_1", "102_2", "102_3", "102_4", "102_5", "102_6", "102_7", "102_8", "102_9", "102_10", "102_11", "102_12", "102_13", "102_14", "102_15", "102_16", "102_17", "102_18", "102_19", "102_20", "102_21", "102_22", "102_23", "102_24", "102_25", "102_26", "102_27", "102_28", "102_29", "102_30", "102_31", "102_32", "102_33", "102_34", "102_35", "102_36", "102_37", "102_38", "102_39", "102_40", "102_41", "102_42", "102_43", "102_44", "102_45", "103_0", "103_1", "103_2", "103_3", "103_4", "103_5", "103_6", "103_7", "103_8", "103_9", "103_10", "103_11", "103_12", "103_13", "103_14", "103_15", "103_16", "103_17", "103_18", "103_19", "103_20", "103_21", "103_22", "103_23", "103_24", "103_25", "103_26", "103_27", "103_28", "103_29", "103_30", "103_31", "103_32", "103_33", "103_34", "103_35", "103_36", "103_37", "103_38", "103_39", "103_40", "103_41", "103_42", "103_43", "103_44", "103_45", "104_0", "104_1", "104_2", "104_3", "104_4", "104_5", "104_6", "104_7", "104_8", "104_9", "104_10", "104_11", "104_12", "104_13", "104_14", "104_15", "104_16", "104_17", "104_18", "104_19", "104_20", "104_21", "104_22", "104_23", "104_24", "104_25", "104_26", "104_27", "104_28", "104_29", "104_30", "104_31", "104_32", "104_33", "104_34", "104_35", "104_36", "104_37", "104_38", "104_39", "104_40", "104_41", "104_42", "104_43", "104_44", "104_45", "105_0", "105_1", "105_2", "105_3", "105_4", "105_5", "105_6", "105_7", "105_8", "105_9", "105_10", "105_11", "105_12", "105_13", "105_14", "105_15", "105_16", "105_17", "105_18", "105_19", "105_20", "105_21", "105_22", "105_23", "105_24", "105_25", "105_26", "105_27", "105_28", "105_29", "105_30", "105_31", "105_32", "105_33", "105_34", "105_35", "105_36", "105_37", "105_38", "105_39", "105_40", "105_41", "105_42", "105_43", "105_44", "105_45", "106_0", "106_1", "106_2", "106_3", "106_4", "106_5", "106_6", "106_7", "106_8", "106_9", "106_10", "106_11", "106_12", "106_13", "106_14", "106_15", "106_16", "106_17", "106_18", "106_19", "106_20", "106_21", "106_22", "106_23", "106_24", "106_25", "106_26", "106_27", "106_28", "106_29", "106_30", "106_31", "106_32", "106_33", "106_34", "106_35", "106_36", "106_37", "106_38", "106_39", "106_40", "106_41", "106_42", "106_43", "106_44", "106_45", "107_0", "107_1", "107_2", "107_3", "107_4", "107_5", "107_6", "107_7", "107_8", "107_9", "107_10", "107_11", "107_12", "107_13", "107_14", "107_15", "107_16", "107_17", "107_18", "107_19", "107_20", "107_21", "107_22", "107_23", "107_24", "107_25", "107_26", "107_27", "107_28", "107_29", "107_30", "107_31", "107_32", "107_33", "107_34", "107_35", "107_36", "107_37", "107_38", "107_39", "107_40", "107_41", "107_42", "107_43", "107_44", "107_45", "108_0", "108_1", "108_2", "108_3", "108_4", "108_5", "108_6", "108_7", "108_8", "108_9", "108_10", "108_11", "108_12", "108_13", "108_14", "108_15", "108_16", "108_17", "108_18", "108_19", "108_20", "108_21", "108_22", "108_23", "108_24", "108_25", "108_26", "108_27", "108_28", "108_29", "108_30", "108_31", "108_32", "108_33", "108_34", "108_35", "108_36", "108_37", "108_38", "108_39", "108_40", "108_41", "108_42", "108_43", "108_44", "108_45", "109_0", "109_1", "109_2", "109_3", "109_4", "109_5", "109_6", "109_7", "109_8", "109_9", "109_10", "109_11", "109_12", "109_13", "109_14", "109_15", "109_16", "109_17", "109_18", "109_19", "109_20", "109_21", "109_22", "109_23", "109_24", "109_25", "109_26", "109_27", "109_28", "109_29", "109_30", "109_31", "109_32", "109_33", "109_34", "109_35", "109_36", "109_37", "109_38", "109_39", "109_40", "109_41", "109_42", "109_43", "109_44", "109_45", "110_0", "110_1", "110_2", "110_3", "110_4", "110_5", "110_6", "110_7", "110_8", "110_9", "110_10", "110_11", "110_12", "110_13", "110_14", "110_15", "110_16", "110_17", "110_18", "110_19", "110_20", "110_21", "110_22", "110_23", "110_24", "110_25", "110_26", "110_27", "110_28", "110_29", "110_30", "110_31", "110_32", "110_33", "110_34", "110_35", "110_36", "110_37", "110_38", "110_39", "110_40", "110_41", "110_42", "110_43", "110_44", "110_45", "111_0", "111_1", "111_2", "111_3", "111_4", "111_5", "111_6", "111_7", "111_8", "111_9", "111_10", "111_11", "111_12", "111_13", "111_14", "111_15", "111_16", "111_17", "111_18", "111_19", "111_20", "111_21", "111_22", "111_23", "111_24", "111_25", "111_26", "111_27", "111_28", "111_29", "111_30", "111_31", "111_32", "111_33", "111_34", "111_35", "111_36", "111_37", "111_38", "111_39", "111_40", "111_41", "111_42", "111_43", "111_44", "111_45", "111_46", "111_47", "111_48", "111_49", "111_50", "112_0", "112_1", "112_2", "112_3", "112_4", "112_5", "112_6", "112_7", "112_8", "112_9", "112_10", "112_11", "112_12", "112_13", "112_14", "112_15", "112_16", "112_17", "112_18", "112_19", "113_0", "113_1", "113_2", "113_3", "113_4", "113_5", "113_6", "113_7", "113_8", "113_9", "113_10", "113_11", "113_12", "113_13", "113_14", "113_15", "113_16", "113_17", "113_18", "113_19", "113_20", "113_21", "113_22", "113_23", "113_24", "114_0", "114_1", "114_2", "114_3", "114_4", "114_5", "114_6", "114_7", "114_8", "114_9", "114_10", "114_11", "114_12", "114_13", "114_14", "114_15", "114_16", "114_17", "114_18", "114_19", "114_20", "114_21", "114_22", "114_23", "114_24", "115_0", "115_1", "115_2", "115_3", "115_4", "115_5", "115_6", "115_7", "115_8", "115_9", "115_10", "115_11", "115_12", "115_13", "115_14", "115_15", "115_16", "115_17", "115_18", "115_19", "115_20", "115_21", "115_22", "115_23", "115_24", "116_0", "116_1", "116_2", "116_3", "116_4", "116_5", "116_6", "116_7", "116_8", "116_9", "116_10", "116_11", "116_12", "116_13", "116_14", "116_15", "116_16", "116_17", "116_18", "116_19", "116_20", "116_21", "116_22", "116_23", "116_24", "117_0", "117_1", "117_2", "117_3", "117_4", "117_5", "117_6", "117_7", "117_8", "117_9", "117_10", "117_11", "117_12", "117_13", "117_14", "117_15", "117_16", "117_17", "117_18", "117_19", "117_20", "117_21", "117_22", "117_23", "117_24", "118_0", "118_1", "118_2", "118_3", "118_4", "118_5", "118_6", "118_7", "118_8", "118_9", "118_10", "118_11", "118_12", "118_13", "118_14", "118_15", "118_16", "118_17", "118_18", "118_19", "118_20", "118_21", "118_22", "118_23", "118_24", "119_0", "119_1", "119_2", "119_3", "119_4", "119_5", "119_6", "119_7", "119_8", "119_9", "119_10", "119_11", "119_12", "119_13", "119_14", "119_15", "119_16", "119_17", "119_18", "119_19", "119_20", "119_21", "119_22", "119_23", "119_24", "120_0", "120_1", "120_2", "120_3", "120_4", "120_5", "120_6", "120_7", "120_8", "120_9", "120_10", "120_11", "120_12", "120_13", "120_14", "120_15", "120_16", "120_17", "120_18", "120_19", "120_20", "120_21", "120_22", "120_23", "120_24", "120_25", "120_26", "120_27", "120_28", "120_29", "120_30", "120_31", "120_32", "120_33", "120_34", "121_0", "121_1", "121_2", "121_3", "121_4", "121_5", "121_6", "121_7", "121_8", "121_9", "121_10", "121_11", "121_12", "121_13", "121_14", "121_15", "121_16", "121_17", "121_18", "121_19", "121_20", "121_21", "121_22", "121_23", "121_24", "121_25", "121_26", "121_27", "121_28", "121_29", "121_30", "121_31", "121_32", "121_33", "121_34", "122_0", "122_1", "122_2", "122_3", "122_4", "122_5", "122_6", "122_7", "122_8", "122_9", "122_10", "122_11", "122_12", "122_13", "122_14", "122_15", "122_16", "122_17", "122_18", "122_19", "122_20", "122_21", "122_22", "122_23", "122_24", "122_25", "122_26", "122_27", "122_28", "122_29", "122_30", "122_31", "122_32", "122_33", "122_34", "123_0", "123_1", "123_2", "123_3", "123_4", "123_5", "123_6", "123_7", "123_8", "123_9", "123_10", "123_11", "123_12", "123_13", "123_14", "123_15", "123_16", "123_17", "123_18", "123_19", "123_20", "123_21", "123_22", "123_23", "123_24", "123_25", "124_0", "124_1", "124_2", "124_3", "124_4", "124_5", "124_6", "124_7", "124_8", "124_9", "124_10", "124_11", "124_12", "124_13", "124_14", "124_15", "124_16", "124_17", "124_18", "124_19", "124_20", "124_21", "124_22", "124_23", "124_24", "124_25", "125_0", "125_1", "125_2", "125_3", "125_4", "125_5", "125_6", "125_7", "125_8", "125_9", "125_10", "125_11", "125_12", "125_13", "125_14", "125_15", "125_16", "125_17", "125_18", "125_19", "125_20", "125_21", "125_22", "125_23", "125_24", "125_25", "126_0", "126_1", "126_2", "126_3", "126_4", "126_5", "126_6", "126_7", "126_8", "126_9", "126_10", "126_11", "126_12", "126_13", "126_14", "126_15", "126_16", "126_17", "126_18", "126_19", "126_20", "126_21", "126_22", "126_23", "126_24", "126_25", "127_0", "127_1", "127_2", "127_3", "127_4", "127_5", "127_6", "127_7", "127_8", "127_9", "127_10", "127_11", "127_12", "127_13", "127_14", "127_15", "127_16", "127_17", "127_18", "127_19", "127_20", "127_21", "127_22", "127_23", "127_24", "127_25", "128_0", "128_1", "128_2", "128_3", "128_4", "128_5", "128_6", "128_7", "128_8", "128_9", "128_10", "128_11", "128_12", "128_13", "128_14", "128_15", "128_16", "128_17", "128_18", "128_19", "128_20", "128_21", "128_22", "128_23", "128_24", "128_25", "129_0", "129_1", "129_2", "129_3", "129_4", "129_5", "129_6", "129_7", "129_8", "129_9", "129_10", "129_11", "129_12", "129_13", "129_14", "129_15", "129_16", "129_17", "129_18", "129_19", "129_20", "129_21", "129_22", "129_23", "129_24", "129_25", "130_0", "130_1", "130_2", "130_3", "130_4", "130_5", "130_6", "130_7", "130_8", "130_9", "130_10", "130_11", "130_12", "130_13", "130_14", "130_15", "130_16", "130_17", "130_18", "130_19", "130_20", "130_21", "130_22", "130_23", "130_24", "130_25", "131_0", "131_1", "131_2", "131_3", "131_4", "131_5", "131_6", "131_7", "131_8", "131_9", "131_10", "131_11", "131_12", "131_13", "131_14", "131_15", "131_16", "131_17", "131_18", "131_19", "131_20", "131_21", "131_22", "131_23", "131_24", "131_25", "132_0", "132_1", "132_2", "132_3", "132_4", "132_5", "132_6", "132_7", "132_8", "132_9", "132_10", "132_11", "132_12", "132_13", "132_14", "132_15", "132_16", "132_17", "132_18", "132_19", "132_20", "132_21", "132_22", "132_23", "132_24", "132_25", "133_0", "133_1", "133_2", "133_3", "133_4", "133_5", "133_6", "133_7", "133_8", "133_9", "133_10", "133_11", "133_12", "133_13", "133_14", "133_15", "133_16", "133_17", "133_18", "133_19", "133_20", "133_21", "133_22", "133_23", "133_24", "133_25", "134_0", "134_1", "134_2", "134_3", "134_4", "134_5", "134_6", "134_7", "134_8", "134_9", "134_10", "134_11", "134_12", "134_13", "134_14", "134_15", "134_16", "134_17", "134_18", "134_19", "134_20", "134_21", "134_22", "134_23", "134_24", "134_25", "135_0", "135_1", "135_2", "135_3", "135_4", "135_5", "135_6", "135_7", "135_8", "135_9", "135_10", "135_11", "135_12", "135_13", "135_14", "135_15", "135_16", "135_17", "136_0", "136_1", "136_2", "136_3", "136_4", "136_5", "136_6", "136_7", "136_8", "136_9", "137_0", "137_1", "137_2", "137_3", "137_4", "137_5", "137_6", "137_7", "137_8", "137_9", "137_10", "137_11", "137_12", "137_13", "137_14", "137_15", "137_16", "137_17", "137_18", "137_19", "137_20", "137_21", "137_22", "137_23", "138_0", "138_1", "138_2", "138_3", "138_4", "138_5", "138_6", "138_7", "138_8", "138_9", "138_10", "138_11", "138_12", "138_13", "138_14", "138_15", "138_16", "138_17", "138_18", "139_0", "139_1", "140_0", "140_1", "140_2", "140_3", "140_4", "140_5", "140_6", "141_0", "141_1", "141_2", "141_3", "141_4", "141_5", "141_6", "141_7", "141_8", "141_9", "141_10", "141_11", "141_12", "141_13", "141_14", "141_15", "141_16", "141_17", "141_18", "142_0", "142_1", "142_2", "142_3", "142_4", "142_5", "142_6", "142_7", "142_8", "142_9", "142_10", "142_11", "142_12", "142_13", "142_14", "142_15", "142_16", "142_17", "142_18", "142_19", "142_20", "142_21", "142_22", "142_23", "142_24", "142_25", "143_0", "143_1", "143_2", "143_3", "143_4", "143_5", "143_6", "143_7", "143_8", "143_9", "143_10", "143_11", "143_12", "144_0", "144_1", "144_2", "144_3", "144_4", "144_5", "144_6", "144_7", "144_8", "144_9", "144_10", "144_11", "144_12"]}